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Introduction 
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Multiple  sclerosis  (MS)  is  a  chronic  disorder  of  the  central  nervous  system  (CNS).  It 
usually starts in young adulthood and leads to cumulative disability. In Groningen the 
prevalence was estimated at 79 per 100000.
1 About 16000 people in the Netherlands have 
MS. Worldwide the number of patients is estimated at 2.5 million.
2 Women are affected 
more frequently than men (ratio male : female = 1 : 2). 
 
The majority of MS patients presents with recurrent episodes of neurological deficit, which 
are  followed  by  complete  or  partial  recovery.  These  episodes  are  called  relapses  or 
exacerbations. This disease course is called relapsing remitting MS.
3 After 10 years 40% 
and after 20 years around 70% of these patients have gradual progression of symptoms 
independent of relapses.
4,5 The disease course is then called secondary progressive. Ten to 
20 % of patients have a primary progressive disease course, in which patients experience 
gradual worsening of symptoms from the beginning of their disease.  Around 25 % of the 
patients with MS have a ‘benign’ disease course. Ten years after onset these patients have 
suffered some exacerbations, but they have recovered well and they are not impaired in 
their daily activities of living.
6 
 
The cause of MS is unknown. Based upon epidemiological, migration and genetic studies, 
it is hypothesized that a genetic predisposition in conjunction with unknown infectious 
agents or other environmental factors, activates the production of auto reactive T cells.
7 
Autoimmune  responses  would  lead  to  focal  inflammatory  demyelination,  which  is 
clinically  expressed  by  relapses.  In  the  cerebrospinal  fluid  of  MS  patients  also  B  cell 
proliferation is found, but it is unknown at what specific antigen this response is aimed.
7 
Next to inflammatory demyelination, axonal injury is a major pathological feature of MS. 
A  number  of  investigators  have  hypothesized  that  dysfunction  of  sodium-calcium 
exchangers, triggers calcium mediated injury, leading to neuronal degeneration.
7 Clinically 
this is expressed by a progressive disease course.  
The  relationship  between  inflammatory  demyelination  and  the  widespread  axonal 
degeneration  is  unknown.  Many  believe  that  the  inflammation  itself  causes  the 
degeneration, directly or after crossing a certain threshold of damage for which the CNS 
can  not  compensate.  Others  think  that  inflammatory  demyelination  and  axonal 
degeneration are two separate entities. 
 
All currently approved treatments of MS are aimed at reducing inflammatory activity. The 
beta-interferons and glatiramer acetate reduce the number of exacerbations with about one 
third.
8,9,10,11 Mitoxantrone and natalizumab are more effective but have potentially serious 
side-effects and can only be used in patients with severe disease activity.
12,13 
 
In 1999 our research group reported that beta-2 adrenergic receptors on astrocytes in MS 
patients  were  deficient.
14  Based  on  this  finding  a  new  hypothesis  was  presented,
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implicating that the resulting decrease in cAMP signaling in the astrocyte might 1) enable 
T cells to turn astrocytes into antigen –presenting cells, which are necessary to initiate the 
inflammatory cascade, and 2) decrease the energy supply to the axons, which would lead to 
axonal degeneration (Figure 1a and Figure 1b
15). 
 
 
 
  
 
Figure  1a.  In  healthy  individuals,  anti-myelin  T  cells  that  have  been  activated  in  the 
periphery  can  penetrate  in  the  CNS  and  secrete  interferon  γ  (IFN-γ)  to  induce  the 
expression  of  major  histocompatibility  (MHC)  class  II  molecules  on  putative  antigen-
presenting cells. In the normal situation, astrocytes are unable to act as antigen-presenting 
cells because noradrenaline acting at β2-adrenoceptors, coupled to the generation of cAMP, 
strongly suppresses IFN-γ-induced expression of MHC class II molecules. Astrocytic β2-
adrenoceptors  also  play  an  important  role  in  stimulating  the  breakdown  of  astrocytic 
glycogen into lactate, which is shuttled to axons and converted into ATP.    4 
 
Figure 1b. Hypothetical model that explains both relapses and progressive disability of 
multiple sclerosis (MS). In MS, astrocytic β2-adrenoceptors are lost, leading to decreased 
cAMP  signaling.  This  might  facilitate  the  expression  of  IFN-γ-induced  MHC  class  II 
molecules and co-stimulatory factors. Binding of the T-cell receptor (TCR) with the MHC 
class  II–antigen  complex  and  appropriate  co-stimulation  (B7  molecules)  can  initiate 
(auto)immune responses that result in relapses of MS. The concerted attack of immune 
cells, cytokines [e.g. tumor necrosis factor-α (TNF-α), interleukin 1 (IL-1)] and nitric oxide 
(NO) released by microglia and astrocytes, and antibodies released from B cells, produces 
areas of demyelination and injury to oligodendrocytes and axons. Within the inflammatory 
lesions, macrophages phagocytose pieces of the myelin sheath. The lack of astrocytic β2-
adrenoceptors  might  also  reduce  cAMP-mediated  glycogenolysis  and  axonal  energy 
supply, particularly in situations of heightened neuronal activity, resulting in progressive 
dysfunction and degeneration of axons.  
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With Magnetic Resonance Imaging (MRI) it is possible to noninvasively ‘view’ the brain. 
Different sequences visualize distinctive pathological features of MS. Dual T2 and FLAIR 
scans show hyperintensities that are typically located in the periventricular white matter, 
and represent both past (the so-called sclerotic plaques or scars) and current inflammation. 
On T1 scans the lesions that enhance after the intravenous administration of contrast are 
representative for active inflammation. Atrophy can be determined on several sequences 
and is indicative of axonal loss. All these techniques are part of the conventional MRI 
work-up. 
 
With  Proton  MR  Spectroscopy  (¹H-MRS),  the  amount  of  N-acetyl  aspartate  (NAA), 
Creatine (Cr), Choline (Cho) and lactate (Lac) can be measured. NAA is found mainly in 
neurons and axons and is considered a marker for axonal metabolism and function. Cr is 
relatively stable in human brain and is commonly used as a reference substance. Cho is a 
cell membrane marker and increases are indicative of glial proliferation. Lac is the product 
of  anaerobic  glycolysis.  The  concentration  of  these  substances  can  change  in  both 
physiological and pathological conditions, such as MS.
16 
Currently MRI is an important tool in diagnosing MS.
17  The appearance of new lesions on 
MRI, even without clinical symptoms, and the existence of many ‘old’ lesions strongly 
support the diagnosis. In phase 2 trials, the initial trials to investigate whether a drug has 
the potential to be effective tested on a small group of patients, the cumulative number of 
enhancing  lesions  on  serial  MR  scans  is  used  as  a  surrogate  marker  for  inflammatory 
activity.
18 Many MRI techniques, including ¹H-MRS, are used for research purposes but do 
not have a common use in clinical practice and clinical trials. 
 
Outline of this thesis 
 
This thesis was initiated after the hypothesis of the loss of the beta-2 adrenergic receptor on 
astrocytes in patients with MS was put forth. The aim was to study in MS patients effects 
of drugs that have been shown to increase the amount of cAMP in the astrocytes. We 
selected the selective serotonin re-uptake inhibitor (SSRI) fluoxetine (Prozac
®), which is 
since 1987 registered for the treatment of depression. Fluoxetine was chosen because it is 
cheap, well-tolerated, safe to use long-term, and has many “neuroprotective” effects that 
might  be  beneficial  in  neurodegenerative  disorders.  In  experimental  allergic 
encephalomyelitis  (EAE),  an  animal  model  of  MS,  fluoxetine-treated  mice  had  less 
inflammation  and  axonal  damage  than  placebo  treated  mice.
19  Since  MS  is  a  chronic 
disease with infrequent disease activity and slow progression of disability, effects of drugs 
are difficult to measure on clinical scales. On cerebral MRI disease activity can be found 
without  clinical  correlates.  Therefore  we  evaluated  different  MRI  methods  to  assess 
efficacy of treatment.  
   6 
This thesis is written in three parts. In the first part (Chapter 2) we review the effects of 
fluoxetine in neurological disorders.  
In the second part we look at conventional MRI methods to measure effects of fluoxetine 
in MS. Chapter 3 described a placebo-controlled study evaluating the effects of fluoxetine 
on new enhancing lesions in patients with MS. In Chapter 4 distinct methods to measure 
brain atrophy are compared. Since the relevance of measuring T2 lesions and brain atrophy 
is unknown, we look at the predictive value of the number and size of T2 lesions and two 
measures of brain atrophy, to the development of secondary progression (Chapter 5) and to 
the occurrence of progression of disability (Chapter 6) after median follow-up times of 14 
and 15 years.   
In the third part we perform several studies with ¹H-MRS to evaluate effects of fluoxetine. 
One component of the hypothesis of the absence of the beta-2 adrenergic receptor implies 
that in patients with MS the production of lactate is decreased. Lactate is produced by 
astrocytes  and  transported  to  axons  as  energy  source  during  periods  of  intense  neural 
activity.
20  In  Chapter 7  we  look at  the  feasibility of  detecting lactate formation in  the 
internal  capsule  of  healthy  subjects  following  contralateral  motor  activity.  If  we  could 
detect  lactate,  we  wanted  to  apply  this  technique  to  MS  patients.  In  Chapter  8  we 
investigate whether NAA/Cr ratios are stable within 4 weeks. In Chapter 9 we report the 
effect of two weeks of fluoxetine treatment on the NAA/Cr ratio. 
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Abstract 
 
The  selective  serotonin  reuptake  inhibitor  (SSRI)  fluoxetine,  which  is  registered  for  a 
variety of psychiatric disorders, has been found to stimulate the cAMP responsive element 
binding protein (CREB), increase the production of brain-derived neurotrophic factor and 
the neurotrophic peptide S100β, enhance glycogenolysis in astrocytes, block voltage-gated 
calcium  and  sodium  channels,  and  decrease  the  conductance  of  mitochondrial  voltage-
dependent anion channels. These mechanisms of actions suggest that fluoxetine may also 
have potential for the treatment of a number of neurological disorders. We performed a 
Pubmed search to review what is known about possible therapeutic effects of fluoxetine in 
animal models and patients with neurological disorders. Beneficial effects of fluoxetine 
have been noted in animal models of stroke, multiple sclerosis and epilepsy. Fluoxetine 
was reported to improve neurological manifestations in patients with Alzheimer’s disease, 
stroke,  Huntington’s  disease,  multiple  sclerosis,  traumatic  brain  injury  and  epilepsy. 
Clinical studies so far were small and often poorly designed. Results were inconclusive and 
contradictory.  However,  the  available  preclinical  data  justify  further  clinical  trials  to 
determine the therapeutic potential of fluoxetine in neurological disorders.  
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Introduction 
 
The  selective  serotonin  reuptake  inhibitor  (SSRI)  fluoxetine  is  widely  used  to  treat 
depression, obsessive-compulsive disorder, bulimia and panic disorder. It became FDA 
approved in 1987.
1 Fluoxetine increases extracellular serotonin (5-HT), which activates 5-
HT receptors. The 5-HT receptors are classified into 7 classes (5-HT 1 to 7) with many 
subclasses. The effect of activation of 5-HT receptors is divers and dependent on the class 
of receptor. The 5-HT system is complex and subject to continuing research.
2 Fluoxetine 
was also found to stimulate 5-HT2 receptors directly.
3,4 
Although  the  precise  mechanism  for  its  beneficial  effects  in  psychiatric  disorders  is 
uncertain,  fluoxetine has  been  shown  to modulate  important cellular functions that  are 
thought  to  be  important  for  neuronal  cell  survival  and  neuroplasticity,  including  the 
regulation of the transcription factor cAMP response element binding protein (CREB), the 
production  of  neurotrophic  factors,  the  regulation  of  neuronal  energy  supply,  and  the 
opening and closing of ion channels.  
The aim of this article is to give an overview of the neurobiological effects of fluoxetine 
that could be useful for the treatment of neurological disorders, and to review the reported 
effects of fluoxetine on neurological disorders and their animal models. We performed a 
PubMed  search  with  the  words  fluoxetine,  and  neurologic(al),  neuroprotection, 
Alzheimer’s  disease,  dementia,  Parkinson’s  disease,  multiple  sclerosis,  stroke, 
Huntington’s  disease,  epilepsy  and  brain  injury.  Articles  only  reporting  effects  on 
psychiatric symptoms were excluded. All available English written reports of animal and 
patient studies published online before May 2007 were included.   
 
Neurobiological effects 
 
An overview of the articles reporting on the neurobiological effects of fluoxetine that could 
be useful for the treatment of neurological disorders is shown in table 1 (page 20). 
 
Effects on CREB and neurotrophic factors 
Chronic  treatment  with  fluoxetine  upregulates  cerebral  CREB  expression  and 
phosphorylation in rats and mice.
5,6,7 CREB is a transcription factor, which induces the 
expression of genes with roles in cell survival, energy metabolism and regeneration.
8 This 
transcription factor is so important that the search for drugs that increase CREB levels has 
been called the search for the ‘Holy Grail of neurological therapeutics’.
9 
 
One of the CREB regulated genes is coding for brain-derived neurotrophic factor (BDNF). 
BDNF is important for the normal development of the human brain and has a critical role 
in  neural  plasticity.
10,11  Decreased  levels  of  BDNF  may  play  a  pivotal  role  in  the   14 
neurodegeneration associated with aging, Huntington’s disease, and Alzheimer’s disease.
10 
Increased BDNF expression was found in multiple sclerosis lesions and proposed as a 
mechanism for neuroprotection.
12 Fluoxetine elevates the concentrations of BDNF in rat 
brain,
13 and enhances the production of S100β in astrocytes.
14,15 S100β, which is mainly 
produced in astrocytes, has paracrine and autocrine effects on neurons and glia. It enhances 
neurogenesis, but leads to apoptosis in high concentration.
16 S100β elevation is associated 
with  treatment  response  in  multiple  sclerosis  patients  on  interferon-β,  and  S100β 
administration in an in vitro model of traumatic brain injury reduced delayed neuronal 
injury.
17,18  
 
Effect of fluoxetine on neuronal energy supply 
The energy supply of neurons is complex and incompletely understood. According to the 
astrocyte-neuron lactate shuttle hypothesis, lactate produced from astrocyte glycogenolysis 
is shuttled to neurons and axons and serves as metabolic fuel, especially during neuronal 
activation.
19,20,21 Fluoxetine is able to enhance glycogenolysis in cultured astrocytes and 
could thus theoretically improve energy supply of axons and neurons.
3,4,22  
 
Effect of fluoxetine on electrolyte channels 
Fluoxetine  inhibits  voltage-gated  calcium  channels  in  rat  cerebral  cells  and  sodium 
channels in bovine adrenal cells.
23,24 This may prevent neurotoxic intracellular calcium 
overload in neurons, which is a key mechanism in neuronal death in both acute conditions, 
such  as  ischemia  and  hypoxia,  and  neurodegenerative  processes.
25,26,27  In  ischemic  rat 
spinal  cord,  white  matter  inhibition  of  the  Na
+/Ca
2+-exchanger  was  found  to  be 
neuroprotective.
28  
 
Fluoxetine  decreased  the  conductance  of  the  mitochondrial  voltage-dependent  anion 
channel (VDAC) in mitochondria isolated from rat liver.
29 VDAC has an important role in 
the release of cytochrome c, an important step in apoptosis. Inhibition of the VDAC by 
fluoxetine protected against staurosporine-induced apoptotic cell death in human U-937 
cells.
29,30  
 
Studies in neurological disorders and their animal models 
 
An overview of the articles reporting effects of fluoxetine in animal models of neurological 
disorders and in patients with neurological disorders is given in tables 2 (page 22) and 3 
(page 25). 
 
 
 
Chapter 2 Chapter 2 
  15 
Parkinson’s disease 
In patients with Parkinson's disease neuronal destruction of the substantia nigra reduces the 
amount of dopamine in the striatum, which impairs motor function. Neuronall cell death 
may be caused by mitochondrial dysfunction resulting in decreased energy production and 
increased intracellular Ca
2+ levels.
31 Fluoxetine might be neuroprotective by preventing 
elevations of intracellular Ca
2+ levels, promoting neuronal energy supply and the release of 
neurotrophic factors by astrocytes.  
 
In a rat model of Parkinson's disease, fluoxetine reduced the availability of extracellular 
dopamine after L-DOPA administration, and it was suggested that SSRIs might worsen 
motor function in patients with Parkinson's disease.
32  
In agreement with this observation, a number of case reports and small studies suggested 
that fluoxetine may worsen motor symptoms in Parkinson's disease.
33,34 However, an open 
pilot study in 14 patients who used fluoxetine 20 mg daily for 1 month found no change in 
rigidity and bradykinesia scores, but a decrease in tremor severity was observed.
35 Another 
open label study of 62 depressed patients with Parkinson's disease showed that SSRIs were 
well  tolerated  and  did  not  change  motor  symptoms  as  measured  with  the  Unified 
Parkinson’s Disease Rating Scale (UPDRS) after 6 months of treatment.
36  
In  three  reports  the  effects  of  repetitive  transcranial  magnetic  stimulation  (rTMS)  and 
fluoxetine in depressed patients with Parkinson's disease were compared. Both fluoxetine 
and rTMS improved the Stroop (coloured words and interference card) and Hooper and 
Wisconsin (perseverative errors) test performances. Increases in regional cerebral blood 
flow (rCBF) in the posterior cingulate gyrus and decreases in the right medial frontal gyrus 
were noted with both fluoxetine and rTMS. Compared with rTMS, fluoxetine intake was 
associated with a relative rCBF increase in the occipital lobe.
37,38 The Mini Mental State 
Examination  (MMSE),
39  which  is  an  11-item  examination  of  cognitive  functions  with 
higher  scores  indicating  better  cognition,  improved  when  both  groups  were  analyzed 
together after 8 weeks. The motor score did not change significantly although there was a 
trend towards worsening in the fluoxetine group.
40 
 
Alzheimer’s disease 
In  Alzheimer’s  disease  amyloid-β  and  tau  make  up  the  plaques  and  tangles  that  are 
believed to cause the progressive neurodegeneration, which leads to dementia. Impaired 
energy  metabolism  is  found  in  Alzheimer’s  disease,  and  an  increase  in  CREB 
phosphorylation  has  been  suggested  to  offer  promise  as  therapeutic  intervention  for 
counteracting neuronal damage in Alzheimer’s disease.
41,42  
 
In a small randomized, double-blind trial, 18 patients with Alzheimer's disease and major 
depression were treated with fluoxetine 10 mg/day and 19 with amitriptyline 25 mg/day 
during 6 weeks.
43 Scores on the MMSE increased significantly with treatment when both   16 
groups were analyzed together. In the fluoxetine group the MMSE increased from 20.0 at 
baseline to 21.4 at day 45.  Dropout rates were very high; 55% for amitriptyline and 22% 
for fluoxetine. A randomized, double-blind trial compared the use of fluoxetine 20 mg/day, 
haloperidol 3 mg/day and placebo in 15 non-depressed patients with disruptive agitated 
behaviors (5 per group) over a period of 6 weeks.
44 Besides more side-effects in the active 
treatment groups no significant differences were found. 
No improvement of MMSE was noticed in a randomized, double-blind, placebo-controlled 
trial of 15 depressed patients on fluoxetine up to 40 mg/day during 6 weeks.
45  
 
In a 8-week, double-blind, placebo-controlled study of 58 non-depressed patients with mild 
cognitive impairment, which may be a prodromal state of Alzheimer's disease, fluoxetine 
improved memory and cognition, measured with the MMSE and subtests from the Persian 
standardized Wechsler Memory Scale ІІІ (WMS-ІІІ).
46 
 
Stroke 
In ischemic stroke neurons die when blood supply falls below the infarction threshold of 8-
10 mL/100 mg/ min. Neurons in the so-called penumbra, where the blood flow is between 
the infarction threshold and the functional threshold of 18-22 mL / 100g/ min, can die due 
to lethal biochemical processes or be rescued by vessel recanalisation or neuroprotective 
interventions. Recovery after stroke is not only dependent on the survival of the neurons in 
the penumbra, but also on brain plasticity. Fluoxetine could be neuroprotective in the acute 
phase (ion channel blocking, enhanced energy metabolism and neurotrophic factor release) 
and improve brain plasticity during stroke rehabilitation (neurotrophic factors). 
 
After induction of focal ischemia in rats, fluoxetine did not alter the degree of recovery of 
function  compared  to  non-treated  rats  after  4  weeks  of  treatment.
47  In  another  study, 
fluoxetine administered 7 days before and up to 28 days after induction of focal cerebral 
ischemia did not influence sensorimotor recovery in rats.
48 However, low dose fluoxetine 
given during 7 days post-partum reduced functional deficits in rats with neonatal hypoxic 
ischemic brain injury.
49  
 
In 8 non-depressed stroke patients, a single dose of fluoxetine appeared to improve motor 
skills  of  the  affected  side.
50  During  rehabilitation  1  to  6  months  after  stroke,  severely 
disabled  patients  showed  significantly  more  often  good  recovery  after  3  months  of 
fluoxetine  treatment,  compared  to  placebo  and  the  norepinephrine  reuptake  inhibitor 
maprotiline.
51 Two other randomized, double-blind, placebo-controlled trials including 104 
and 31 stroke patients were mainly focused on the antidepressant effects of fluoxetine and 
found  no  benefit  on  functional  recovery  after  respectively  45  days  and  12  weeks  of 
treatment.
52,53  
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Spalletta et al. looked at the effect of sertraline (n=21) and fluoxetine 20 mg (n=29) on 
patients  with  and  without  alexithymia,  a  condition  in  which  patients  have  problems 
identifying and coping with feelings. A significant increase of MMSE after 8 weeks of 
treatment in the 32 patients without alexithymia was noticed.
54 
 
Huntington’s disease 
In patients with Huntington’s disease the slowly progressive neuronal loss in the basal 
ganglia causes a movement disorder (characteristic chorea) together with a cognitive and 
affective disorder. An altered energy metabolism is hypothesized to be important in the 
pathophysiology of Huntington’s disease.
55 Fluoxetine might have a neuroprotective effect 
by increasing energy metabolism and the production of BDNF.  
 
Two  patients  with  Huntington's  disease  responded  well  to  fluoxetine  treatment.  Both 
showed  motor  improvement  and  one  patient's  cognitive  functions  also  improved. 
Beneficial effects did take 4-6 months to develop and lasted several years.
56 A randomized, 
double-blind, placebo-controlled trial in non-depressed Huntington's disease patients failed 
to show substantial clinical benefits of fluoxetine treatment after 4 months, although a 
slight reduction in agitation and in the need for routine care was found.
57  
 
Multiple sclerosis 
In the beginning of their disease about 80% of the patients with multiple sclerosis have 
symptoms that come and go (relapses) resulting from focal inflammatory demyelination in 
the central nervous system (CNS). After 10 to 20 years most patients experience gradual 
increasing  disability,  which  is  caused  by  a  more  diffuse  progressive  axonal  loss. 
Mitochondrial failure, which gives dysfunction of electrolyte channels and leads eventually 
to toxic intracellular calcium overload, is suspected to play a pivotal role in the axonal 
dysfunction and degeneration in multiple sclerosis.
58 By improving energy metabolism and 
by blocking  sodium  channels, fluoxetine  might  protect axons in  patients  with  multiple 
sclerosis. 
 
In mice with chronic relapsing experimental allergic encephalomyelitis (EAE), an animal 
model for the inflammatory lesions of multiple sclerosis, fluoxetine prevented worsening 
of  neurological  signs,  prolonged  survival,  and  reduced  CNS  inflammation  and  axonal 
damage compared to untreated animals.
59  
 
In a letter to the editor a psychiatrist reported a patient with multiple sclerosis who suffered 
a  worsening  of  symptoms  after  initiating  treatment  with  fluoxetine.
60  A  number  of 
psychiatrists replied that multiple sclerosis patients on treatment with fluoxetine on the 
contrary remained quite stable.
61  
   18 
In a preliminary open study of 11 patients with multiple sclerosis, 2 weeks of fluoxetine 
administration  increased  cerebral  white  matter  N-acetylaspartate  levels  on  magnetic 
resonance  spectroscopy,  suggesting  an  improvement  in  axonal  mitochondrial  energy 
production.
62 Trends towards an improvement of walking ability and fatigue were also 
noted.  
 
Traumatic brain injury 
Trauma to the head causes permanent and reversible damage to neurons. Improved energy 
metabolism  and  increased  production  of  neurotrophic  factors  by  the  administration  of 
fluoxetine might prevent irreversible loss of neurons and promote plasticity in patients with 
traumatic brain injury. 
 
In a rat model of moderate to severe traumatic brain injury, fluoxetine treatment during 15 
days did not improve motor performance.
63 
 
In an open-label investigation of 5 head-injured patients, fluoxetine not only improved 
mood, but had also a beneficial effect on several measures of cognition after 8 months of 
treatment.
64  
 
Epilepsy 
Epilepsy  is  caused  by  a  reduced  membrane  stability  of  neurons.  Both  genetic 
predisposition  and  neuronal  damage  increase  the  susceptibility  for  epileptic  seizures. 
Treatment is aimed at increasing the membrane stability. By blocking sodium and calcium 
channels fluoxetine might improve membrane stability.  
Fluoxetine  reduced  seizure  activity  in  many  animal  models  of  epilepsy.
65,66,67,68,69,70 
However,  one  study  reported  an  increase  in  epileptic  activity  after  treatment  with 
fluoxetine in a rat epilepsy model.
71 
 
In an open-label, add-on trial of fluoxetine in patients with complex partial seizures with 
and without secondary generalization, 6 patients showed complete disappearance of their 
seizures and the remaining 11 patients had a 30% reduction in seizure frequency.
72 
It is stated that despite some case reports of worsening of seizure activity, antidepressant 
drugs can have anticonvulsant effects when used in usual dosages.
73,74 
 
Discussion 
 
Caution should be taken to extrapolate the results of in vitro studies to in vivo effects. In 
cell cultures the concentration of fluoxetine used (1-50 µM) mostly exceed therapeutic 
plasma levels in patients (1-3 µM) and the effect of fluoxetine might be overestimated. 
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However, drug concentrations of fluoxetine in the human brain are reported to be 20 fold 
higher than plasma levels
75 and concentrations of up to 50 µM might thus be reached in the 
human brain.  
Beneficial effects of fluoxetine were noted in animal models of stroke, multiple sclerosis 
and epilepsy. In these studies higher dosages of the medication (1.0 -20 mg/kg/day) were 
used than in clinical use (20-80 mg/day; = 0.25 – 1.0 mg/kg/day) and the results must 
therefore also be regarded cautiously. In patients with Parkinson’s disease, fluoxetine was 
well tolerated but no positive effects on symptoms of the disease process were reported. In 
Alzheimer’s disease one positive study was found in mild cognitive impairment. The other 
studies had only 6 weeks of follow-up and could not find beneficial effects. In stroke 
patients initial claims of a beneficial effect of fluoxetine on motor recovery could not be 
confirmed in a larger study with longer follow-up. In Huntington’s disease a relatively 
large, well-designed trial with 4 months of follow-up could not find better performance of 
patients treated with fluoxetine compared to placebo-treated patients. In epilepsy, multiple 
sclerosis and traumatic brain injury good studies are lacking.  
Many clinical studies were performed in depressive patients, and it is uncertain whether 
improvement of neurological symptoms was influenced by improvement of the underlying 
depression.  Also  it  is  difficult  to  measure  effects  in  neurodegenerative  disorders  since 
progression is slow, clinical scales are insensitive and good surrogate markers are lacking. 
Underestimation of therapeutic effect is possible since at least several weeks of treatment 
are necessary before plasma levels of fluoxetine become stable.
76 
Small studies with a number of other SSRIs have also shown an indication for a possible 
beneficial effect in some neurological disorders: paroxetine and citalopram in patients with 
Parkinson’s disease,
77,78 sertraline in patients with traumatic brain injury,
79 and citalopram 
and fluvoxamine in patients with epilepsy.
80,81,82,83,84 Since distinct SSRIs have different 
affinities for the serotonin receptors it is not possible to generalize the results of fluoxetine 
to all other SSRIs. 
Although clinical studies so far are inconclusive, the preclinical findings justify further 
trials with fluoxetine and perhaps other SSRIs in patients with neurological disorders.  
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Abstract 
 
By  enhancing  intracellular  cAMP  signalling  in  astrocytes  fluoxetine  might  be  able  to 
suppress  the antigen presenting capacity  of glial cells  in multiple  sclerosis  (MS).  This 
study was designed to evaluate the effects of fluoxetine on new lesion formation in patients 
with relapsing MS.  
In a double-blind, placebo-controlled exploratory trial, forty non-depressed patients with 
relapsing  remitting  or  relapsing  secondary  progressive  MS  were  randomised  to  oral 
fluoxetine 20 mg or placebo daily for 24 weeks. New lesion formation was studied by 
assessing  the  cumulative  number  of  gadolinium-enhancing  lesions  on  brain  MRI 
performed on weeks 4, 8, 16 and 24.  
Nineteen patients in both groups completed the study. The mean (SD) cumulative number 
of new enhancing lesions during the 24 weeks of treatment was 1.84 (2.9) in the fluoxetine 
group and 5.16 (8.6) in the placebo group (p=0.15). The number of scans showing new 
enhancing lesions was 25 % in the fluoxetine group vs 41 % in the placebo group (p=0.04). 
Restricting  the  analysis  to  the  last  16  weeks  of  treatment  showed  that  the  cumulative 
number of new enhancing lesions was 1.21 (2.6) in the fluoxetine group and 3.16 (5.3) in 
the placebo group (p=0.05). The number of patients without enhancing lesions was 63 % in 
the fluoxetine group vs 26 % in the placebo group (p=0.02). 
This proof-of-concept study shows that fluoxetine tends to reduce the formation of new 
enhancing lesions in patients with MS. Further studies with this compound are warranted. 
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Introduction 
 
Focal inflammatory demyelinating lesions in multiple sclerosis (MS) are believed to result 
from autoreactive T cell-mediated processes.
1,2 The inflammatory cascade and the resultant 
lesion formation in MS is contingent upon the ability of activated anti-myelin T cells to 
recognise their specific antigen in the context of class II major histocompatability complex 
(MHC)  molecules  expressed  on  the  membrane  of  antigen  presenting  glial  cells.
1,2 
Medications  currently  used  or  under  development  for  the  treatment  of  MS  target  the 
peripheral immune system. Inhibition of MHC class II expression on glial cells would 
represent a novel therapeutic approach to suppress disease activity in MS.  
 
Whether microglia or astrocytes represent the principal CNS antigen presenting cells in 
MS remains a controversial issue. Many neuroimmunologists consider microglia as the 
primary immunoeffector cells in MS because they constitutively express MHC class II 
antigens.
3  An  alternative  hypothesis  proposes  that  astrocytes  play  an  important  role  as 
facultative antigen presenting cells.
4 In contrast to microglia, MHC class II expression on 
astrocytes under normal conditions is severely restricted by regulatory influences, some of 
which are mediated by intracellular cAMP signalling pathways.
5,6 A role of astrocytes as 
facultative  antigen  presenting  cells  in  MS  is  supported  by  the  findings  that  scattered 
astrocytes in active MS lesions express MHC class II and B-7 costimulatory molecules.
7,8 
Our group has postulated the hypothesis that this  may be attributed to reduced cAMP 
signalling in astrocytes caused by a loss of beta-2 adrenergic receptors.
4,9,10 
 
The objective of this study was to provide proof of concept that enhancing intracellular 
cAMP signalling pathways in astrocytes in patients with MS reduces inflammatory disease 
activity. We selected fluoxetine, which is a selective serotonin-reuptake inhibitor (SSRI) 
widely prescribed for depression, bulimia and obsessive compulsive disorders. Astrocytes, 
including those in MS lesions, contain serotonin receptors and reuptake sites, and serotonin 
has  been  shown  to  elevate  cAMP  levels  in  astrocytes.
11,12,13  Furthermore,  prolonged 
exposure to SSRIs activates intracellular cAMP signalling in the CNS of animals.
14,15 We 
conducted a double-blind, placebo-controlled, exploratory study to assess the effects of 
fluoxetine on inflammatory disease activity in patients with a relapsing form of MS by 
using serial gadolinium-enhanced brain MRI.  
 
Methods 
 
Subjects 
The local medical ethics committee approved the protocol. All patients provided written 
informed consent. Eligible patients were aged 18 to 65 years with clinically definitive   42 
relapsing  remitting  or  relapsing  secondary  progressive  MS.
16,17  Additional  inclusion 
criteria were an Expanded Disability Status Score (EDSS)
 of less or equal to 6, and at least 
one  relapse  in  the  preceding  year,  or  two  relapses  in  the  preceding  two  years,  or  one 
gadolinium-enhancing lesion on the screening MRI of the brain. Exclusion criteria were 
the  use  of  immunomodulatory,  immunosuppressive  or  antidepressants  drugs  in  the 
previous 6 months, the use of corticosteroids in the previous 8 weeks, depression defined 
as  a  score  of  19  or  higher  on  Beck’s  Depression  Inventory  ІІ,
18  bipolar  disorder, 
contraindication to MRI, other neurological or systemic disorder that would interfere with 
the assessments, and pregnancy or unwillingness to use acceptable birth control. 
 
Study design 
In this single-centre, double-blind, placebo-controlled study 40 patients were randomised 
to receive a single tablet of fluoxetine 20 mg or identical placebo daily in the morning for 
24  weeks.  After  a  screening  visit  and  brain  MRI  4  weeks  prior  to  start  of  the  study 
medication, patients visited the clinic for brain MRI and clinical evaluation at weeks 0, 4, 
8,  16  and  24.  Disability  status  was  assessed  at  baseline  and  week  24.  The  hospital 
pharmacy produced the study medication and performed the randomisations. The code was 
revealed to the researchers once the follow-up of all patients and the MRI analyses were 
completed. One physician was responsible for all clinical assessments. Relapses could be 
treated with high dose corticosteroids for 5 consecutive days.  
 
MRI protocol and processing 
All scans were performed on a 3.0 Tesla scanner (Philips). Brain transaxial Dual TSE 
(repetition  time, 3000 msec; echo  times,  26.7 and 120  msec), FLAIR (repetition  time, 
11,000 msec; echo time, 100 msec) and T1-weighted (repetition time, 700 msec; echo time, 
8.4 msec) images before and after intravenous administration of gadolinium (0.1 mmol/kg) 
with 51 contiguous slices of 3 mm thickness were obtained at each visit.  
 
The scans were blindly analysed in the Department of Radiology of the Leiden University 
Medical  Center.  T1  enhancing  lesions  were  determined  according  to  published 
guidelines.
19  T2 lesion volume was segmented with a semi-automated home-developed 
software program called SNIPER.
20 
 
Outcome measures 
The primary outcome measure was the cumulative number of new gadolinium-enhancing 
lesions during the treatment phase. Other MRI outcome measures included the number of 
scans showing new enhancing lesions, the number of scans showing enhancing lesions, the 
number  of  patients  with  no  enhancing  lesions,  the  change  in  T2  lesion  volume  and 
cumulative new T1 gadolinium enhancing lesion volume.  
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Secondary clinical endpoints were number of relapses, number of patients with relapses, 
and changes in EDSS and Multiple Sclerosis Functional Composite (MSFC). The MSFC is 
a multidimensional test consisting of a task for leg function (timed 25-foot walk), arm 
function  (9-hole  peg  test)  and  cognition  (paced  auditory  serial  addition  test).  Its  score 
represents the mean of the z- scores of the three tests, which are calculated in comparison 
to a pooled reference population.
21 Lower scores indicate more disability.  Exploratory 
analyses of MRI data in the first 8 weeks and last 16 weeks were performed separately to 
assess possible time dependent effects of fluoxetine treatment. 
 
Statistical analysis 
Because this was an exploratory study and because it is difficult to define a relevant effect 
of fluoxetine we did not perform a power calculation. The aim of our study was to collect 
information about an effect size, and if any to use this effect size in the design of future 
studies. 
 
All data were tested for normality. Baseline and between treatment comparisons of the 
number and volume of T1 enhancing lesions, T2 lesion load, and EDSS were evaluated 
with  the  Wilcoxon-Mann-Whitney  rank-sum  test.  For  baseline  and  between  treatment 
comparisons of the MSFC the independent samples t-test was used. The χ² test and Fisher’s 
exact  test  were  used  to  compare  differences  in  categorical  variables.  Analyses  were 
performed with the Statistical Package for the Social Sciences (SPSS 14.0 for Windows, 
Chicago, Illinois). All reported p values are two-tailed. Significance was taken at 0.05. 
 
Results 
 
Patients 
Between April 2004 and August 2006, 65 patients were screened, after which 40 were 
found eligible for inclusion. Figure 1 shows the flow of the patients. In the first week after 
randomisation one patient in the fluoxetine group and one patient in the placebo group 
withdrew because of nausea. All other patients completed the study and were used in the 
analyses. There were no significant differences between the two groups in baseline MRI, 
clinical or demographic characteristics (Table 1). 
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Figure 1 Patient flowchart. 
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Table 1 Patient Characteristics.  
  Fluoxetine 
(n=19) 
Placebo 
(n=19) 
p  
Mean age (y) (SD)  41 (10)  38 (9)  0.34 
Sex (M/F)  9/10  9/10  1.00 
Disease course: RR/SP  18/1  16/3  0.60 
Mean time from first symptoms (y) (SD)  11 (7)  11 (8)  0.97 
Median number of exacerbations in the last 
2 years (range) 
2 (1 – 3)  2 (0 – 3)  0.62 
Median EDSS (range)  3.0 (0.0 – 6.0)  3.0 (1.0 – 5.5)  0.95 
Mean MSFC (SD)  0.18 (0.6)  0.10 (0.6)  0.70 
Number of new enhancing lesions at 
baseline 
    0.56 
  Mean (SD)  0.63 (1.3)  0.58 (0.8)   
  Median (range)  0 (0 – 5)  0 (0 – 3)   
Scans showing enhancing lesions baseline   7 (37%)  8 (42%)  0.74 
T2 lesion load (mm
3)      0.54 
  Mean (SD)  4761 (6414)  5527 (6891)   
  Median (range)  1894  
(670 –20829) 
2946  
(80 –28496) 
 
 RR = relapsing remitting; SP = secondary progressive; EDSS = Expanded Disability Status Scale; MSFC = 
Multiple Sclerosis Functional Composite 
 
 
Efficacy 
Table 2 shows MRI outcomes over the 24-week study period.  
The  mean  cumulative  number  of  new  enhancing  lesions  tended  to  be  lower  in  the 
fluoxetine group than in the placebo group, but this was not significant (p=0.15). However, 
compared to the placebo group, there were significantly less scans with new enhancing 
lesions in the fluoxetine group (p=0.04). The fluoxetine group also showed a trend toward 
a reduction in the cumulative volume of new enhancing lesions, the number of scans with 
enhancing lesions, and increase of the T2 lesion load.  
Figure 2 shows the time-dependent changes in mean cumulative number of new enhancing 
lesions from the start of treatment.  
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Table 2 MRI outcomes over the 24-week study period. 
  Fluoxetine  
(n=19) 
Placebo  
(n=19) 
p 
Cumulative number of new enhancing 
lesions  
    0.15 
  Mean (SD)  1.84 (2.9)  5.16 (8.6)   
  Median (range)  1 (0 – 12)  2 (0 – 35)   
Cumulative volume of new enhancing 
lesions (mm
3) 
    0.16 
  Mean (SD)  124 (278)  398 (745)   
  Median (range)  22 (0 – 1191)  77 (0 – 3063)   
Number of patients with no new 
enhancing lesions  
6 (32%)  4 (21%)  0.71 
Scans showing new enhancing lesions   19 (25%)  31 (41%)  0.04 
Scans showing enhancing lesions   22 (29%)  33 (43%)  0.06 
Change in T2 lesion load (mm
3)      0.10 
  Mean (SD)  444 (958)  531 (1004)   
  Median (range)  128  
(-506 – 2930) 
475  
(-1907 – 2391) 
 
 
 
Exploratory analysis revealed no differences in MRI outcome measures between the two 
groups up to the first 8 weeks of treatment. Analysis of disease activity during the last 16 
weeks (Table 3) showed a nearly significant reduction in the cumulative number (p=0.05) 
and  volume  (p=0.06)  of  new  enhancing  lesions,  and  a  lower  number  of  scans  with 
enhancing (p=0.03) or new enhancing lesions (p=0.03) in the fluoxetine group compared to 
the placebo group. The fluoxetine group contained a higher number of patients with no 
new enhancing lesions (p=0.02).  
Number of relapses, and changes in EDSS and MSFC were comparable between the two 
groups (Table 4).  
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Figure 2 Boxplots of the cumulative number of new enhancing lesions per treatment group 
over time. 
 
 
Table 3 MRI outcomes during the last 16 weeks. 
  Fluoxetine (n=19)  Placebo (n=19)  p 
Cumulative number of new enhancing 
lesions 
    0.05 
  Mean (SD)  1.21 (2.6)  3.16 (5.3)   
  Median (range)  0 (0 – 11)  1 (0 – 22)   
Cumulative volume of new enhancing 
lesions (mm
3) 
    0.06 
  Mean (SD)  90 (231)  227 (485)   
  Median (range)  0 (0 – 961)  35 (0 – 2095)   
Number of patients with no new 
enhancing lesions  
12 (63%)  5 (26%)  0.02 
Scans showing new enhancing lesions  9 (24%)  18 (47%)  0.03 
Scans showing enhancing lesions   9 (24%)  18 (47%)  0.03 
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Table 4 Clinical outcomes. 
  Fluoxetine  
(n=19) 
Placebo 
(n=19) 
Number of exacerbations   4   6  
Number of patients with exacerbations  4 (21%)  5 (26%) 
Median change in EDSS (range)  0.0 (-2.0 – 1.5)  0.0 (-1.5 – 1.0) 
Mean change in MSFC (SD)  0.075 (0.38)  0.049 (0.14) 
EDSS  =  Expanded  Disability  Status  Scale;  MSFC  =  Multiple  Sclerosis  Functional 
Composite  
 
Safety and tolerability 
In general fluoxetine was well tolerated. Patients using fluoxetine suffered more often from 
nausea  and  drowsiness  (Table  5).  Most  adverse  events  were  at  the  start  of  the  study 
medication and diminished after a few days to weeks.  
 
Table 5 Adverse events.  
  Fluoxetine  
(n=20) 
Placebo  
(n=20) 
p 
Nausea  13 (65%)  6 (30%)  0.03 
Headache  4 (20%)  6 (30%)  0.72 
Dizziness  5 (25%)  7 (35%)  0.49 
Drowsiness  11 (55%)  6 (30%)  0.11 
Insomnia  2 (10%)  2 (10%)  1.00 
Transpiration  2(10%)  1 (5%)  1.00 
Palpitations  2 (10%)  -  0.49 
Loss of appetite  2 (10%)  -  0.49 
 
 
Discussion 
 
In this study, patients with the relapsing form of MS treated with fluoxetine showed a trend 
toward a reduction in the number of new enhancing lesions over time. This effect became 
apparent  after  8  weeks  of  treatment,  suggesting  that  it  takes  several  weeks  before 
fluoxetine becomes effective. Fluoxetine plasma concentrations are gradually build up and 
achieve  steady-state  conditions  only  after  several  weeks,
22  and  it  is  well  known  that 
patients  with  depression  need  treatment  for  a  number  of  weeks  before  effects  become 
clinically evident.  
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Conclusions from our results must be made with caution because of the small sample size 
and exploratory design. Retrospective power calculation shows that we were only able to 
detect treatment effects above 80% with a statistical power of 80%.
23 The treatment with 
fluoxetine was shown to be safe and well tolerated. 
 
The results lend support to the hypothesis that elevating cAMP signalling in astrocytes may 
reduce inflammatory disease activity in patients with MS.  
An increase  in  cAMP signalling in  astrocytes downregulates the  class II transactivator 
protein,
24 thereby suppressing the induction by proinflammatory cytokines of MHC class II 
molecules.
25 This mechanism is thought to prevent the deviation of astrocytes to function 
as  facultative  immunocompetent  CNS  antigen  presenting  cells  that  can  mediate 
inflammatory  events.  Possible  influences  of  fluoxetine  on  microglia  or  cells  of  the 
peripheral immune system cannot be dismissed, but are unlikely. In vitro studies showed 
that elevation of intracellular cAMP levels suppresses interferon-γ induction of MHC class 
II in astrocytes, but not in microglial cells.
6 In vitro experiments on human lymphocyte 
suspensions  showed  that  fluoxetine  decreases  lymphocyte  proliferation  and  suppresses 
interferon-γ  production.
26  However,  these  effects  were  only  found  with  fluoxetine 
concentrations of 10-50 µM, which are far in excess of therapeutic plasma concentrations. 
Serum levels of fluoxetine with daily doses ranging from 20 to 40 mg vary between 0.26 
and 0.65 µM,
27 making it unlikely that immunomodulatory effects of fluoxetine on T cells 
were involved in our study.  
 
An interesting aspect of considering fluoxetine as a candidate drug for the treatment of MS 
are its additional mechanisms of action that might be relevant for reducing axonal loss, 
leading  to  progressive  disability.  These  include  the  production  by  astrocytes  of 
neurotrophic factors such as brain-derived neurotrophic factor,
28 stimulation of astrocyte 
glycogenolysis,
29 and blockage of sodium channels.
30 Sodium channel activation,
31 and 
reduced axonal energy metabolism caused by impaired glycogenolysis in astrocytes,
10 have 
been hypothesized to play a role in the axonal degeneration in MS. In patients with MS, 
fluoxetine improved the cerebral white matter N-acetylaspartate/creatine ratio, which can 
be regarded as a measure of axonal energy metabolism.
32 
 
The results of our exploratory trial are sufficiently encouraging to justify further studies 
with fluoxetine in patients with MS. Higher doses of fluoxetine and combination treatment 
with immunomodulatory drugs should be considered.  
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Abstract 
The objective of this study was to compare different measures of brain atrophy in patients 
with relapsing multiple sclerosis (MS).  
We determined in a cross-sectional study in 33 patients with relapsing MS the bicaudate 
ratio (BCR), third ventricle width (TVW), corpus callosum area (CCA), brain parenchymal 
fraction (BPF), grey matter fraction (GMF), white matter fraction (WMF), and T2 lesion 
load.  Correlations  with  the  Expanded  Disability  Status  Scale  (EDSS)  and  Multiple 
Sclerosis Functional Composite (MSFC) were performed. 
Except for CCA, all atrophy measurements correlated with each other. Only TVW and 
BCR did not correlate with the T2 lesion load. The EDSS correlated with TVW (r=0.45). 
The MSFC correlated significantly with TVW, BPF, WMF and GMF (r= 0.46 to r= 0.53).  
We  conclude  that  the  BPF,  WMF,  GMF  and  TVW  show  a  moderate  correlation  with 
clinical disability. BPF might be best to use in clinical trials. The TVW is of particular 
interest because it does not seem to be influenced by the T2 lesion load.  
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Introduction 
 
Brain  atrophy,  which  is  a  normal  process  of  aging,  is  accelerated  in  individuals  with 
multiple sclerosis (MS).
1,2,3,4,5 Progressive brain volume loss in relapsing MS can already 
be detected on magnetic resonance imaging (MRI) over a period of one year, and early in 
the disease course.
3,6,7,8,9,10 Progressive atrophy seems to be caused by the typical focal 
lesions (plaques) and an apparently focal lesion-independent diffuse axonal degeneration.
6  
Brain atrophy has been proposed as a surrogate marker to monitor disease progression and 
treatment  efficacy  in  MS.
11,12,13  In  the  many  studies  evaluating  brain  atrophy  in  MS 
different methods have been used.
6,14,15  
It is unclear whether the measured degree of atrophy in patients with MS is dependent on 
the technique used and, if so, what technique is most suitable to use in clinical trials. 
Therefore we compared several techniques to quantify brain atrophy in MS on brain MRI: 
the bicaudate ratio (BCR), third ventricle width (TVW), corpus callosum area (CCA), brain 
parenchymal fraction (BPF), and grey and white matter fraction (GMF and WMF). We 
assessed the correlations of the different atrophy measurements with each other, clinical 
disability and T2 lesion load.  
 
Methods 
 
Subjects 
The study population consisted of 33 patients with clinically definite MS with relapses (28 
relapsing-remitting, 5 relapsing secondary progressive). None of the patients was using 
immunomodulating medication and all patients were relapse free for at least 8 weeks at the 
time  of  scanning.  Disease  duration  was  defined  as  the  time  from  first  symptoms 
attributable to the MS.  
 
Disability measurements 
Disability was measured with the Expanded Disability Status Scale (EDSS) and Multiple 
Sclerosis Functional Composite (MSFC).
16,17 The EDSS ranges from 0 to 10, with higher 
scores indicating more severe disease. The MSFC is a multidimensional clinical outcome 
measure that includes quantitative tests of leg function/ambulation (timed 25-foot walk; 
T25W), arm function (9-hole peg test; 9HPT) and cognitive function (paced auditory serial 
addition test; PASAT). The score on each assessment is converted to a Z score and the 
composite score is computed according to a standardised formula.
18 
 
MRI protocol 
MRI  scans  were  performed  on  a  3.0-T  unit  (Philips  Medical  Systems,  Best,  The 
Netherlands). In the same session transaxial Dual TSE (repetition time, 3000 milliseconds;   56 
echo times, 26.7 and 120 milliseconds), FLAIR (repetition time, 11000 milliseconds; echo 
time, 100 milliseconds) with 51 contiguous slices of 3mm, and high resolution 3D T1-
weighted (HR3D-T1; repetition time, 7.5 milliseconds; echo time, 3.4 milliseconds) with 
160 contiguous slices of 1 mm of the brain were obtained. 
 
MRI analysis 
T2 lesion load was quantified by fully automatic segmentation on axial dual fast spin echo 
sequences using fuzzy clustering. Details are described elsewhere.
19  
 
Atrophy was determined by three manual linear or area measurements: BCR, TVW, CCA, 
and two semi-automated brain volume measurement: the BPF, and the GMF -WMF. The 
three manual measures were performed on the T1 weighted images; the dual echo scan was 
used to determine the anterior commissure (AC)-posterior commissure (PC) plane. 
 
  
Figure 1  
A) Calculation of BCR: length of grey line divided by 
length of white line.  
B) Determination of TVW.  
C) Assessment of CCA: by adjusting the grey scale 
the corpus callosum area is highlighted. 
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BCR is defined as the minimum intercaudate distance divided by brain width along the 
same line (Fig. 1A). Compared to other MS studies which use the slice where the heads of 
the caudate nuclei are most visible and closest to another,
20 we measured the BCR on the 
slice 10 mm superior to the AC-PC plane.
21 This way of determining the slice is also used 
in Huntington's disease studies and is more objective.  
 
TVW was measured by drawing a linear region of interest perpendicular to the long axis of 
the third ventricle parallel to the interhemispheric fissure in the section wherein the third 
ventricle was most visible (Fig. 1B).
22 
 
CCA was determined by outlining the margins on the mid-sagittal slice (Fig. 1C).  
To  determine  intra-observer  and  inter-observer  reproducibility  of  the  three  linear 
measurements, 17 scans were analysed twice by the same observer (IV) and 6 by a second 
observer (JM). 
 
Figure  2  Semi-automatic  measurement  of  BPF:  the  parenchyma  (yellow)  volume  is 
divided by the intracranial (yellow and blue) volume. The intracranial volume is manually 
edited when necessary.   58 
BPF is a normalised measure, which is calculated as total brain volume divided by total 
intracranial volume (Fig. 2). Fully automated segmentation of whole brain and intracranial 
volume was performed on the dual T2 and FLAIR images, using fuzzy C-means with in-
house  developed  software  (SNIPER:  Software  for  Neuro  Image  Processing  in 
Experimental  Research,  Laboratory  for  Clinical  and  Experimental  Image  Processing, 
Department of Radiology, LUMC). Brain and non-brain structures were manually edited or 
removed. Details are described elsewhere.
19  
 
The GMF and WMF were determined using SPM2 software. The HR3D-T1 images were 
spatially normalized and segmented in native space into GM and WM images.
23,24 The GM 
and  WM  segmentation  maps  were  visually  checked  for  misclassification  and  adjusted 
when necessary. 
 
Statistics 
Pearsons’  correlation  coefficients  were  used  to  calculate  correlations  between  different 
atrophy measurements.  
 
Relations between atrophy measurements and the MSFC were assessed with Pearsons’ 
correlation coefficients, the relationship between atrophy measurements and EDSS and T2 
lesions load were analysed with Spearman rank correlation coefficients.  
 
Inter-observer  en  intra-observer  reproducibility  of  the  three  linear  measurements  was 
assessed with the coefficient of variation (COV = 100 * standard deviation of the mean 
difference / [√2 *pooled mean values]).
25  
 
To correct for multiple testing, significance was taken at a p value < 0.01. All statistical 
analyses  were  done  using  SPSS  statistical  software  package  version  14.0  (SPSS  Inc, 
Chicago, USA).  
 
 
Results 
 
Baseline characteristics 
Demographic, clinical and MRI characteristics of the MS patients are shown in Table 1.  
Chapter 4 Chapter 4 
  59 
Table 1 Characteristics of the patients. 
Number of patients  33 
Gender:  Male (%)  14 (42) 
Age (years): mean (SD)  39.4 (9.4) 
Disease duration (years): mean (SD)  11.5 (7.2) 
EDSS score: Mean (SD)/ median(range)  3.1 (1.5) / 3.0 (0 – 6.0) 
MSFC score: mean (SD)  0.154 (0.629) 
T2 lesion volume (cc): mean (SD)  5.4 (6.8) 
BCR: mean (SD)  0.114 (0.035) 
TVW (mm): mean (SD)  3.8 (2.2) 
CCA (mm
2): mean (SD)  593 (131.2) 
BPF: mean (SD)  0.88 (0.02) 
WMF: mean (SD)  0.27 (0.021) 
GMF: mean (SD)  0.37 (0.027) 
EDSS = Expanded Disability Status Scale; MSFC = Multiple Sclerosis Functional Composite; BCR = bicaudate 
ratio; TVW = third ventricle width; CCA = corpus callosum area; BPF = brain parenchymal fraction; WMF = 
white matter fraction, GMF = grey matter fraction 
 
 
Table 2 Correlations among atrophy measurements. 
    r  P 
BCR  Vs. TVW  0.80  <0.001 
  Vs. CCA  -0.17  0.33 
  Vs. BPF  -0.51  0.003 
  Vs. GMF  -0.55  0.001 
  Vs. WMF  -0.49  0.004 
TVW  Vs. CCA  -0.38  0.03 
  Vs. BPF  -0.47  0.006 
  Vs. GMF  -0.46  0.007 
  Vs. WMF  -0.61  < 0.001 
CCA  Vs. BPF  0.48  0.005 
  Vs. nGMF  0.37  0.04 
  Vs. nWMF  0.61  < 0.001 
BPF  Vs. GMF  0.76  < 0.001 
  Vs. WMF  0.76  < 0.001 
GMF  Vs. WMF  0.47  0.005 
BCR = bicaudate ratio; TVW = third ventricle width; CCA = corpus callosum area; BPF = brain parenchymal 
fraction; WMF = white matter fraction, GMF = grey matter fraction. The level of significance was taken as a p 
value < 0.01. 
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Correlations between atrophy measurements 
Table 2 summarises correlations between different brain atrophy measures. CCA correlated 
well with WMF, moderately with BPF, but not with the other atrophy measures. All other 
atrophy values correlated significantly with each other. The strongest correlations were 
found between TVW and BCR, and between BPF and both GMF and WMF.  
 
 
Table 3 Correlations between atrophy measures and clinical scores, age, disease duration 
and T2 lesion load. 
    r  P      r  P 
BCR  Vs. EDSS  0.27  0.13  BPF  Vs. EDSS  -0.37  0.032 
  Vs. MSFC  -0.43  0.014    Vs. MSFC  0.53  0.001 
  Vs. age  0.47  0.006    Vs. age  -0.36  0.037 
  Vs. disease 
duration 
0.41  0.017    Vs. disease 
duration 
-0.28  0.11 
  Vs. T2 lesion 
load 
0.23  0.20    Vs. T2 lesion 
load 
-0.47  0.005 
TVW  Vs. EDSS  0.45  0.009  GMF  Vs. EDSS  -0.41  0.017 
  Vs. MSFC  -0.51  0.003    Vs. MSFC  0.46  0.006 
  Vs. age  0.35  0.047    Vs. age  -0.42  0.016 
  Vs. disease 
duration 
0.36  0.042    Vs. disease 
duration 
-0.49  0.004 
  Vs. T2 lesion 
load 
0.26  0.14    Vs. T2 lesion 
load 
-0.45  0.009 
CCA  Vs. EDSS  -0.41  0.019  WMF  Vs. EDSS  -0.34  0.056 
  Vs. MSFC  0.33  0.063    Vs. MSFC  0.47  0.006 
  Vs. age  -0.31  0.079    Vs. age  -0.23  0.20 
  Vs. disease 
duration 
-0.20  0.27    Vs. disease 
duration 
-0.15  0.41 
  Vs. T2 lesion 
load 
-0.61  < 
0.001 
  Vs. T2 lesion 
load 
-0.46  0.007 
BCR = bicaudate ratio; TVW = third ventricle width; CCA = corpus callosum area; BPF = brain parenchymal 
fraction; WMF = white matter fraction, GMF = grey matter fraction; EDSS = Expanded Disability Status Scale; 
MSFC = Multiple Sclerosis Functional Composite. 
The level of significance was taken as a p value < 0.01. 
 
 
Relation between clinical disability, T2 lesion load and atrophy measurements 
As shown in Table 3, correlations were found between T2 lesion volume and BPF, GMF, 
WMF and CCA, but not with TVW and BCR. The EDSS was only correlated to TVW. The 
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MSFC correlated with BPF, GMF, WMF and TVW, but not with the BCR and CCA. The 
strongest correlation was with the BPF (Fig. 3).  
 
 
Figure 3 Correlation of the BPF with the MSFC (P = 0.001). 
 
 
Reproducibility of linear brain atrophy measurements 
The coefficients of variation (COV) for intra-observer reliability of BCR, TVW and CCA 
were  4.4%,  5.3%  and  2.5%.  The  COVs  for  inter-observer  reliability  of  these  linear 
measurements were 3.6%, 8.9% and 2.4%, respectively. 
 
Discussion 
 
Except for CCA, all atrophy measurements correlated to each other. This suggests that the 
process that leads to atrophy has global as well as local anatomical impact. It indicates that 
the measured degree of atrophy is more dependent on the amount of ‘true’ atrophy than on 
the technique used.  
The strong correlation between BCR and TVW might reflect degeneration of the axons in 
the  internal  capsule.  These  two  measurements  had  no  correlation  with  T2  lesion  load, 
adding support to the hypothesis that the progressive central neurodegeneration in MS runs 
independently of the development of the focal lesions. In contrast BPF, GMF, WMF and 
CCA correlated with T2 lesion volume, supporting the idea that central and global brain 
atrophy may have a different pathophysiological background.
14 CCA correlated best with   62 
WMF and T2 lesion load, indicating that CCA is an appropriate measure of white matter 
disease burden. A comparable correlation between CCA and T2 lesion load was found 
previously.
8 
 
In agreement with Kallmann and colleagues we found a significant correlation between 
TVW  and  the  EDSS.
26  The  third  ventricle  divides  the  thalamic  hemispheres  and  the 
adjacent posterior limbs of the internal capsule, and both thalamic and internal capsule 
atrophy  may  give  rise  to  ex  vacuo  enlargement  of  the  third  ventricle.  Other  atrophy 
measurements did not correlate significantly with the EDSS, but there were trends toward 
weak and moderate correlations (Table 2). 
These  correlations  between  EDSS  and  atrophy  measurements  are  in  agreement  with 
previous observations,
27,28,29 and may be explained by the fact that this functional score is 
heavily  weighted  towards  assessment  of  leg  function.
30  Deterioration  of  ambulation  is 
mainly caused by spinal cord involvement.  
The  MSFC  was  developed  to  overcome  the  limitations  of  the  EDSS  and  might  thus 
represent  better  the  overall  clinical  disability  of  MS  patients.  We  found  a  significant 
correlation  between  the  MSFC  and  TVW,  BPF,  GMF  and  WMF.  A  previous  study 
reported also that  the MSFC correlated better to the BPF than the EDSS did, and a recent 
study in 117 subjects with secondary progressive MS found similar results.
31,32 In this last 
study  the  normalized  brain  volume  (NBV),  a  measure  comparable  to  BPF,  had  the 
strongest correlation with the MSFC score, was a significant independent predictor of the 
MSFC, and was proposed as the atrophy measurement to use in clinical trials.
32 Since in 
our  study  with  relapsing  MS  patients  the  MSFC  was  best  explained  by  BPF,  we  can 
support  the  recommendation  of  the  use  of  techniques  like  BPF  and  NBV  to  measure 
atrophy in MS trials. 
 
Measurement of the CCA appeared to be the best reproducible manual measurement of 
brain  atrophy in  our as well as in  previous  studies.
8,20,28  TVW measurement was least 
reproducible. This may be attributed to the way of selecting the slice. Although we agreed 
in advance to use the middle one of a serial of appropriate slices and in doubt the one with 
the widest ventricle, there wasn’t always consensus.  
 
Linear,  manually  determined  atrophy  measures  are  methodologically  simple. 
Disadvantages are the observer's bias, low accuracy compared to automated techniques, 
and time consuming analysis. (Semi-) automated methods are faster, more accurate and 
better reproducible.
14,27 
 
Main limitations of our study are the low number of patients and the absence of patients 
with an EDSS higher than 6.0, which may reduce the ability to find stronger correlations 
between atrophy measurements and clinical scores. 
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In conclusion, we show that all atrophy measurements except for CCA are correlated. CCA 
appears to be a good measure of white matter disease burden. The BPF, WMF, GMF and 
TVW correlate with clinical disability. BPF might be the best atrophy measurement to use 
in clinical trials. The TVW is of particular interest because there is no correlation with the 
T2 lesion load, and may represent a more pure surrogate of the diffuse axonal degeneration   
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References 
 
  1.   Fox NC, Jenkins R, Leary SM et al. Progressive cerebral atrophy in MS: a serial 
study using registered, volumetric MRI. Neurology. 2000; 54; 807-812. 
  2.   Ingle GT, Stevenson VL, Miller DH et al. Primary progressive multiple sclerosis: a 
5-year clinical and MR study. Brain. 2003; 126; 2528-2536. 
  3.   Losseff  NA,  Wang  L,  Lai  HM  et  al.  Progressive  cerebral  atrophy  in  multiple 
sclerosis. A serial MRI study. Brain. 1996; 119 ( Pt 6); 2009-2019. 
  4.   Stevenson VL, Miller DH, Leary SM et al. One year follow up study of primary and 
transitional  progressive  multiple  sclerosis.  J.Neurol  Neurosurg.Psychiatry.  2000; 
68; 713-718. 
  5.   Courchesne E, Chisum HJ, Townsend J et al. Normal brain development and aging: 
quantitative analysis at in vivo MR imaging in healthy volunteers. Radiology. 2000; 
216; 672-682. 
  6.   Miller DH, Barkhof F, Frank JA et al. Measurement of atrophy in multiple sclerosis: 
pathological basis, methodological aspects and clinical relevance. Brain. 2002; 125; 
1676-1695. 
  7.   Rudick RA, Fisher E, Lee JC et al. Use of the brain parenchymal fraction to measure 
whole  brain  atrophy  in  relapsing-remitting  MS.  Multiple  Sclerosis  Collaborative 
Research Group. Neurology. 1999; 53; 1698-1704. 
  8.   Simon JH, Jacobs LD, Campion MK et al. A longitudinal study of brain atrophy in 
relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group 
(MSCRG). Neurology. 1999; 53; 139-148. 
  9.   Tiberio M, Chard DT, Altmann DR et al. Gray and white matter volume changes in 
early RRMS: a 2-year longitudinal study. Neurology. 2005; 64; 1001-1007. 
  10.   Zivadinov R, Sepcic J, Nasuelli D et al. A longitudinal study of brain atrophy and 
cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. 
J.Neurol Neurosurg.Psychiatry. 2001; 70; 773-780. 
  11.   Filippi M, Rovaris M, Iannucci G et al. Whole brain volume changes in patients 
with progressive MS treated with cladribine. Neurology. 2000; 55; 1714-1718. 
  12.   Frank JA, Richert N, Bash C et al. Interferon-beta-1b slows progression of atrophy 
in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology. 2004; 62; 
719-725. 
  13.   Paolillo A, Pozzilli C, Giugni E et al. A 6-year clinical and MRI follow-up study of 
patients  with  relapsing-remitting  multiple  sclerosis  treated  with  Interferon-beta. 
Eur.J.Neurol. 2002; 9; 645-655. 
  14.   Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in 
multiple sclerosis. Lancet Neurol. 2006; 5; 158-170. 
Chapter 4 Chapter 4 
  65 
  15.   Zivadinov R, Reder AT, Filippi M et al. Mechanisms of action of disease-modifying 
agents and brain volume changes in multiple sclerosis. Neurology. 2008; 71; 136-
144. 
  16.   Fischer  JS,  Rudick  RA,  Cutter  GR  et  al.  The  Multiple  Sclerosis  Functional 
Composite  Measure  (MSFC):  an  integrated  approach  to  MS  clinical  outcome 
assessment.  National  MS  Society  Clinical  Outcomes  Assessment  Task  Force. 
Mult.Scler. 1999; 5; 244-250. 
  17.   Kurtzke  JF.  Rating  neurologic  impairment  in  multiple  sclerosis:  an  expanded 
disability status scale (EDSS). Neurology. 1983; 33; 1444-1452. 
  18.   Fischer JS, Jack AJ, Knicker JE et al. Administration and Scoring Manual for the 
Multiple Sclerosis Functional Composite Measure (MSFC). New York, NY: Demos 
Medical Publishing, Inc. 1999.  
  19.   Admiraal-Behloul  F,  van  den  Heuvel  DM,  Olofsen  H  et  al.  Fully  automatic 
segmentation  of  white  matter  hyperintensities  in  MR  images  of  the  elderly. 
Neuroimage. 2005; 28; 607-617. 
  20.   Bermel  RA,  Bakshi  R,  Tjoa  C  et  al.  Bicaudate  ratio  as  a  magnetic  resonance 
imaging marker of brain atrophy in multiple sclerosis. Arch.Neurol. 2002; 59; 275-
280. 
  21.   Barr  AN,  Heinze  WJ,  Dobben  GD  et  al.  Bicaudate  index  in  computerized 
tomography of Huntington disease and cerebral atrophy. Neurology. 1978; 28; 1196-
1200. 
  22.   Benedict  RH,  Weinstock-Guttman  B,  Fishman  I  et  al.  Prediction  of 
neuropsychological impairment in multiple sclerosis: comparison of conventional 
magnetic resonance imaging measures of atrophy and lesion burden. Arch.Neurol. 
2004; 61; 226-230. 
  23.   Ashburner  J,  Friston  KJ.  Nonlinear  spatial  normalization  using  basis  functions. 
Hum.Brain Mapp. 1999; 7; 254-266. 
  24.   Ashburner  J,  Friston  KJ.  Voxel-based  morphometry--the  methods.  Neuroimage. 
2000; 11; 805-821. 
  25.   van der Worp HB, Claus SP, Bar PR et al. Reproducibility of measurements of 
cerebral infarct volume on CT scans. Stroke. 2001; 32; 424-430. 
  26.   Kallmann BA, Sauer J, Schliesser M et al. Determination of ventricular diameters in 
multiple sclerosis patients with transcranial sonography (TCS)--a two year follow-
up study. J.Neurol. 2004; 251; 30-34. 
  27.   Sharma  J,  Sanfilipo  MP,  Benedict  RH  et  al.  Whole-brain  atrophy  in  multiple 
sclerosis measured by automated versus semiautomated MR imaging segmentation. 
AJNR Am.J.Neuroradiol. 2004; 25; 985-996. 
  28.   Bermel RA, Sharma J, Tjoa CW et al. A semiautomated measure of whole-brain 
atrophy in multiple sclerosis. J.Neurol Sci. 2003; 208; 57-65.   66 
  29.   Sanfilipo MP, Benedict RH, Sharma J et al. The relationship between whole brain 
volume and disability in multiple sclerosis: a comparison of normalized gray vs. 
white matter with misclassification correction. Neuroimage. 2005; 26; 1068-1077. 
  30.   Whitaker  JN,  McFarland  HF,  Rudge  P  et  al.  Outcomes  assessment  in  multiple 
sclerosis clinical trials: a critical analysis. Mult.Scler. 1995; 1; 37-47. 
  31.   Kalkers  NF,  Bergers  E,  Castelijns  JA  et  al.  Optimizing  the  association  between 
disability and biological markers in MS. Neurology. 2001; 57; 1253-1258. 
  32.   Furby J, Hayton T, Anderson V et al. Magnetic resonance imaging measures of 
brain  and  spinal  cord  atrophy  correlate  with  clinical  impairment  in  secondary 
progressive multiple sclerosis. Mult.Scler. 2008; 14; 1068-1075. 
    
 
 
 
 
Chapter 4  
  67 
Chapter 5 
 
 
 
 
Relationship between the extent of T2 lesions and the 
onset of secondary progression in multiple sclerosis 
 
J.P. Mostert
1, J.C. de Groot
2, G.S.M. Ramsaransing
1, M.W. Koch
1, J. De 
Keyser
1 
 
Author’s affiliations:  
1 Department of Neurology, University Medical Centre Groningen, 
University of Groningen, Groningen, The Netherlands 
2 Department of Radiology, University Medical Centre Groningen, 
University of Groningen, Groningen, The Netherlands 
 
 
 
 
 
 
 
 
 
 
 
 
 
European Journal of Neurology 
2007 Nov;14(11):1210-5.Chapter 5 
  68 
Abstract 
 
Patients with relapsing remitting multiple sclerosis (MS) are at risk of converting to a 
secondary  progressive  disease  course.  To  assess  the  relationship  between  brain  MRI 
findings and onset of secondary progression, we reanalysed the initial brain MRI scans of 
90 relapsing remitting MS patients, who were clinically followed for at least 10 years 
(median 14 years) after their scan, for the number and volume of T2 lesions, and for two 
measures of brain atrophy (bicaudate ratio and third ventricle width). The relationship to 
development  of  secondary  progression  was  studied  with  Cox  regression  models  and 
Kaplan-Meier  survival  analyses.  At  the  end  of  follow-up  36  patients  had  become 
progressive.  The  presence  of  more  than  10  T2  lesions  more  than  doubled  the  risk  of 
becoming secondary progressive (hazard ratio: 2.36; 95% CI: 1.19 – 4.66). When at least 
one of the 10 lesions was confluent the risk increased to 3.51 (1.64 – 7.50). The hazard 
ratio for an estimated T2 lesion load of more than 3400* mm
3 was 2.11 (1.07 – 4.16). 
Linear brain atrophy measures were not predictive. Our data show a relationship between 
the extent of brain T2 lesions and the onset of secondary progression in MS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* compared to the published article the T2 lesion load was multiplied by 
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Introduction 
 
The majority of patients with multiple sclerosis (MS) present with relapses, which are 
followed by variable degrees of recovery, spontaneously or in response to corticosteroids. 
Within 10 years after the first clinical manifestation approximately 30-40%, and within 20 
years  around  70%,  of  the  patients  convert  to  a  secondary  progressive  phase,  which  is 
characterized by a steady progression of clinical disability independent of relapses.
1,2,3,4 At 
present, there are no established measures to predict the onset of the secondary progressive 
phase.  
 
Relapses  of  MS  are  caused  by  focal  lesions  in  eloquent  areas  of  the  CNS,  whereas 
secondary  progression  results  from  a  more  diffuse  degeneration  of  axons.
5,6  The 
mechanism underlying conversion from a relapsing remitting disease course to secondary 
progressive MS is unknown. The aim of this study was to assess whether findings on the 
base-line brain MRI are related to a more rapid onset of the secondary progressive phase. 
Do patients with early onset of secondary progression have early signs of brain atrophy or 
is there a relationship with the extent of existing white matter lesions? To answer these 
questions we reanalysed a cohort of patients with relapsing remitting MS who had a brain 
MRI scan performed between 1987 and 1995 as part of the diagnostic work-up and who 
were followed up for at least 10 years. 
 
Methods 
 
Patients 
The  Groningen  MS  database  was  established  in  1985.  Data  of  patients  attending  the 
Groningen MS clinic are systematically entered when a patient is first seen and at each of 
the regular follow-up visits (from 3 to 12 months).  
 
Of the 454 patients with definite MS with a relapsing disease onset
7 in our database, 249 
had a brain MRI-scan before 1996. Seventy-six patients were already progressive at the 
time of scanning, 81 scans had been destroyed, and 2 patients were lost to follow-up within 
10 years, leaving 90 patients for analysis. Patient characteristics were comparable between 
included and not included patients (Table 1).  
 
Disability was measured with the Expanded Disability Status Scale (EDSS; scores can 
range from 0 to 10, with higher scores indicating more severe disease).
8 The onset of the 
secondary progressive phase (the onset of gradual worsening of MS symptoms for at least 
12 months unrelated to relapse
4) was available in the database, and was verified.    70 
Table 1 Characteristics of the patients with relapsing remitting MS in the Groningen MS 
database (median, IQR). 
Characteristics  Participating 
patients 
All other relapsing 
remitting patients in 
database 
All other relapsing 
remitting patients 
with a MRI-scan 
before 1996 
Number of patients  90  364  83 
Gender: male (%)/ 
female (%) 
25 (28%) / 65 
(72%) 
111 (30%) / 253 
(70%) 
26 (31%) / 57 
(69%) 
Age at start disease  29.5 (23.75 – 36)  29 (23 – 26)  29 (23 – 33) 
Age at time of the 
MRI scan (years) 
33 (26 – 40.25)    31 (28 – 38) 
Disease duration at 
time of scanning 
(years) 
1 (0 – 6.25)    2 (0 – 6) 
Number of patients 
that become 
progressive 
36 (40%)    33 (40%) 
 
MRI 
MRI was performed on a 1.5 Tesla scanner which was available in the University Hospital 
Groningen from 1987 (Philips Gyroscan S15). Slice thickness was 5 mm in most patients 
(n=67), and 6, 9 and 10 mm in the remainder (1, 3 and 19 patients respectively). Because 
not all standard sequences were available, only T2-weighted scans were evaluated. The 
hardcopies of all scans were analyzed by an experienced neuroradiologist (J.C. de G.), who 
was  unaware  of  the  clinical  data.  Lesions  were  classified  by  region  (supratentorial, 
infratentorial)  and  by  size  (small  <  5  mm;  medium  5  –  10  mm;  large  >  10  mm,  or 
confluent). Confluent lesions were defined as single T2 lesions larger than 20 mm typically 
located in the periventricular region, or as two or more T2 lesions connected at one or more 
margins.
9 We estimated the total lesion volume by assuming the lesions were spherical 
with a fixed diameter size per category.
10  
 
Bicaudate ratio and third ventricle width were used as measures of brain atrophy.
11,12 The 
bicaudate ratio is the minimal distance between both caudate nuclei divided by the brain 
width at the same level, measured on the axial slice where the caudate nuclei are best 
visible. Third ventricle width is the maximal diameter of the third ventricle. 
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Statistical analyses 
To  estimate  the  predictive  value  of  brain  MRI  findings  on  conversion  to  secondary 
progression,  we  performed  Cox  proportional-hazards  regression  analyses  to  calculate 
hazard  ratios  with  adjustment  for  age  at  time  of  scanning,  disease  duration  at  time  of 
scanning,  and  gender.  T2  lesion  number,  T2  lesion  load,  third  ventricle  width  and 
bicaudate ratio were entered as continuous variables. We also studied confluent lesions, 
infratentorial lesions, and increasing cut-off points of T2 lesion number, T2 lesion load, 
third ventricle width and bicaudate ratio. The time-to-event was the time between the MRI 
scan and the start of the progressive phase or to the date of the last follow-up visit if 
progression had not developed. Time-to-event curves describing the proportion of patients 
becoming secondary progressive during the whole follow-up period were calculated by the 
Kaplan-Meier method, and compared using log-rank tests. 
Between group comparisons were performed with Mann-Whitney tests or with Chi-Square 
tests  when  appropriate.  Correlation  coefficients  were  calculated  with  Spearman’s  rank 
correlation  test.  Significance  was  taken  at  the  two-tailed  0.05  level.  Analyses  were 
performed with the Statistical Package for the Social Sciences (SPSS 12.0 for Windows, 
Chicago, Illinois). 
 
Results 
 
Patients 
Baseline characteristics of the participating patients are listed in Table 2. 
 
Brain MRI data 
Double  reading  was  performed  for  a  random  set  of  24  scans.  Intra-class  correlation 
coefficients were excellent for T2 lesion load (r = 0.96; p < 0.001), T2 lesion number (r = 
0.95; p < 0.001) and third ventricle width (r = 0.99, p < 0.001), and good for bicaudate 
ratio (r = 0.82; p < 0.001).  
 
The number of T2 lesions ranged from 0 to 80. The EDSS score was not documented at the 
time of the MRI scan in 8 patients and ranged from 0 to 5.0. There was no correlation 
between the EDSS at time of scanning and either T2 lesion load (r = 0.056; p = 0.62) or T2 
lesion number (r = 0.13; p =0.24). Disease duration at time of scanning was not correlated 
to T2 lesion number (r = 0.051; p = 0.63) or T2 lesion load (r = -0.031; p = 0.78). Twenty-
eight patients were already diagnosed with clinically definite MS at the time of scanning; 
the other 62 patients were definitively diagnosed with MS in the year of their initial MRI-
scan or in the years thereafter. In 4 patients, the infratentorial part of the brain was missing 
on the MRI scan. In the analysis the number of infratentorial lesions for these patients was   72 
set to 0. Excluding these 4 patients from the analysis did not change the results (data not 
shown). 
 
Table 2 Patient characteristics (median, IQR). 
Characteristics  All patients  Patients not 
progressive at 
follow-up  
Patients progressive 
at follow-up  
Number of patients  90  54  36 
Gender: male (%)/ female 
(%) 
25 (28%)/ 65 (72%)  13 (24%)/ 41 (76%)  12 (33%)/ 24 (67%) 
Age at time of the MRI 
scan (years) 
33 (26 – 40)  32.5 (25 – 39)  34.5 (29 – 44) 
Disease duration at time of 
scanning (years) 
2.5 (0 – 6.25)  1.5 (0 – 6)  3 (1 – 7) 
Time between scanning and 
diagnosis (years) 
0 (0 – 2)  0 (0 – 2)  0 (0 – 2) 
Follow-up after the MRI 
scan (years) 
14 (12 – 16)  14 (12 – 15)  15 (13 – 16) 
EDSS at time of scanning
#  2 (1 – 2.625)  1.5 (1 – 2)  2 (1.5 – 3.5)** 
Bicaudate ratio   0.11 (0.10 – 0.13)  0.11 (0.10 – 0.13)  0.11 (0.10 – 0.14) 
Third ventricle width (mm)  1.00 (0.50 – 1.25)  1.00 (0.50 – 1.00)  1.00 (0.63 – 1.5) 
T2 lesion load (mm³)  1648 (250 – 3636)  1347 (243 – 2879)  2551 (351 – 4366) 
Total number of T2 lesions  9.5 (4 – 19)  7 (4.75 – 14)  14.5 (3.25 – 25.5) 
Number of patients with > 
10 T2 lesions 
40 (44%)  18 (33%)  22 (61%)** 
Number of patients with 
infratentorial lesions
$ 
14 (16%)  7 (14%)  7 (21%) 
Number of patients with 
confluent lesions  
24 (27%)  10 (19%)  14 (39%)* 
Number of patients with  > 
10 T2 lesions including at 
least one confluent lesion  
20 (22%)  6 (11%)  14 (39%)** 
 
#N = 82, 
$N = 86 
*p < 0.05, ** p < 0.01: patients progressive at follow-up compared to patients not progressive at follow-up. 
 
 
 
 
 
Chapter 5 Chapter 5 
  73 
Thirty-six patients (40%) had become progressive over a median follow-up period of 14 
years. Twenty-three patients (64%) who entered the progressive phase had been treated 
with immunomodulatory therapy (20 with interferon-β, 2 with monthly methylprednisolon 
infusions, and 1 with azathioprine) compared to 8 of 54 patients (15%) who remained 
relapsing remitting (5 with interferon-β, 2 with monthly methylprednisolon infusions, and 
1 with azathioprine). 
 
The results of Cox proportional-hazards regression analyses are shown in Table 3. Higher 
T2 lesion number and load increased the risk of becoming secondary progressive. This risk 
increased with higher cut-off points of T2 lesion number and T2 lesion load. The presence 
of more than 10 T2 lesions, a T2 lesion load of more than 3400 mm³, or the presence of at 
least one confluent lesion more than doubled the risk of becoming secondary progressive. 
The presence of more than 10 T2 lesions, including at least one confluent lesion, more than 
tripled the risk of entering the progressive phase of the disease when compared to patients 
with up to 10 T2 lesions (HR 3.51; 95% CI: 1.64 – 7.50). The presence of infratentorial 
lesions did not increase the risk of becoming progressive. The relationship between T2  
 
Table 3 Hazard ratios of developing secondary progression for several MRI findings. 
  Number of 
subjects 
Hazard 
Ratio 
95% confidence 
interval 
P-value 
Bicaudate ratio    0.079  0 – 2.2*10
4  0.69 
    Ratio > 0.11  48  0.71  0.34 – 1.45  0.34 
    Ratio > 0.12  34  0.1  0.39 – 1.66  0.56 
    Ratio > 0.14  19  0.89  0.39 – 2.0  0.78 
Third ventricle width     1.10  0.65 – 1.87  0.72 
     > 1.0 mm  21  1.07  0.49 – 2.34  0.87 
Number of T2 lesions    1.02  1.01 – 1.04  0.005 
    > 5 T2 lesions  58  1.49  0.71 – 3.14  0.29 
    > 10 T2 lesions  40  2.36  1.19 – 4.66  0.01 
    > 15 T2 lesions  28  2.57  1.33 – 4.98  0.005 
    > 25 T2 lesions  14  2.99  1.34 – 6.66  0.008 
    Infratentorial lesions  14  1.70  0.70 – 4.10  0.24 
    Confluent lesions  24  2.23  1.13 – 4.39  0.02 
    > 10 T2 lesions including at  
    least one confluent lesion 
20  3.10  1.57 – 6.13  0.001 
T2 lesion load    1.00  1.000 – 1.001  0.04 
    > 400 mm
3   63  1.01  0.48 – 2.13  0.98 
    > 2100 mm
3  40  1.84  0.94 – 3.59  0.08 
    > 3400 mm
3   25  2.11  1.07 – 4.16  0.03 
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lesion number or T2 lesion load and the risk of secondary progression was not altered 
when the EDSS was included as a covariate (data not shown). Brain atrophy measures, 
disease duration, age and gender were not predictive.  
 
Kaplan Meier survival analyses showed that the probability of entering the progressive 
phase was significantly higher in patients with more than 10 T2 lesions than in patients 
with 10 or fewer T2 lesions (P = 0.007, Figure 1A).  
 
 
Figure 1 Kaplan-Meier estimates for secondary progression for patients with up to 10 T2 
lesions (N=50) compared to (A) patients with more than 10 T2 lesions (N=40) and (B) 
patients with more than 10 T2 lesions including at least one confluent lesion (N=20) (B). 
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Of  the  50  patients  with  10  or  fewer  T2  lesions,  a  quarter  (13  patients)  had  become 
progressive at 13 years, and 28% (14 patients) at the end of follow-up. Of the 40 patients 
with more than 10 T2 lesions, a quarter (10 patients) had already become progressive at 3 
years, half (20 patients) at 8 years and 55% (22 patients) at the end of follow-up. The 
probability of entering the progressive phase was even more pronounced when comparing 
patients with more than 10 T2 lesions, of which at least one lesion was confluent, with 
patients who had 10 or fewer T2 lesions (P < 0.001, Figure 1B).  
 
Discussion 
 
In this study we investigated brain MRI characteristics of patients with relapsing remitting 
MS  in  relation  to  subsequent  onset  of  secondary  progression.  We  found  a  strong 
relationship  between  the  extent  of  T2  lesions  and  the  onset  of  secondary  progression. 
Although signs of brain atrophy can occur early in the disease course of MS,
13 we found no 
association between early brain atrophy and onset of secondary progression.  
 
In patients with clinically isolated syndromes suggestive of MS, it has been shown that 
increases in the volume of brain T2 lesions in the first five years correlate with the degree 
of long-term disability as measured with the EDSS.
14 In another study of 156 patients with 
clinically isolated syndromes EDSS at 5 years correlated moderately (r = 0.43) with the 
number  of  baseline  T2  lesions.
15  A  study  on  30  relapsing  remitting  patients  found  a 
correlation between T2 lesion load and disability 13 years later.
16 However, disability can 
develop from both incomplete recovery from relapses and gradual progression. We did not 
focus on disability but investigated the onset of the progressive phase.  
 
Some limitations of our study should be noted. The sample size is relatively small and 
because of the long follow-up it is possible that patients with a benign disease course are 
underrepresented.  However,  the  percentage  of  patients  that  became  progressive  during 
follow-up is similar to that reported in natural history studies.
1,3,4 The scans were analysed 
retrospectively, but interpretation bias is unlikely because the neuroradiologist who scored 
the  scans  had  no  knowledge  of  the  clinical  data.  Since  our  patients  were  scanned  for 
clinical purposes, the scanning protocol was inconsistent and follow-up scans are lacking. 
Our method of manually estimating T2 lesion load and using linear brain atrophy measures 
may  be  less  precise  than  the  current  automated  methods.  On  the  other  hand,  the 
measurements performed were highly reproducible. At the time of scanning our cohort had 
variable disease duration, age and EDSS, but we corrected our analyses for these three 
variables. 
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In two studies investigating the conversion of patients with clinically isolated syndromes to 
definite MS, the median number of T2 lesions at the baseline MRI-scan was 4 in the study 
with a low conversion rate and 18 in the study with a high conversion rate.
17,18 Thus, the 
median number of lesions of 9.5 in our study is representative for patients with relapsing 
MS at the beginning of their disease. 
 
Focal lesions of MS are primarily due to episodes of T-cell-mediated inflammatory activity 
causing demyelination, axonal injury and gliosis,
5,6,19 while the progressive phase of MS 
appears to be driven by relentless axonal degeneration. Several observations indicate that 
different  effector  mechanisms  underlie  the  development  of  focal  lesions  and  the 
progressive phase of MS. First, the progression of disability in secondary progressive MS 
is not affected by relapses, neither by those occurring before the onset of the progressive 
phase  nor  by  those  occurring  during  this  phase.
1,4  Second,  medications  such  as  beta 
interferons, glatiramer acetate and immunosuppressive drugs, which reduce relapses and 
suppress  the  inflammatory  component  of  the  disease,  are  unable  to  slow  down  the 
progressive phase.
2 Third, MRI and neuropathological investigations found no correlation 
between  CNS  focal  lesion  load  and  the  diffuse  axonal  loss  in  the  spinal  cord  that 
characterises the progressive phase of MS.
20,21  
Our finding that the extent of focal T2 lesions predicts the onset of the progressive phase 
seems  in  conflict  with  these  observations.  A  plausible  explanation  for  this  apparent 
contradiction is that a higher number of focal white matter lesions facilitates the clinical 
expression of the progressive phase. The
 CNS has a large functional reserve capacity. Even 
in a tract
 system with clearly defined and measurable clinical function,
 as the pyramidal 
tract, permanent clinical deficit is only
 seen when more than 60% of the axons in the tract 
system are
 lost.
22 If we assume that the slowly progressive axonal degeneration follows a 
similar course in the majority of MS patients, clinical manifestations of progression will 
start earlier in those patients who have lost more reserve capacity due to CNS tissue injury 
in focal lesions. Confluent lesions represent a large area of focal lesions and this might 
explain the striking association between confluent lesions and transition to the progressive 
phase. 
 
There is no consensus on the time when treatment with immunomodulatory drugs should 
be  started,  or  whether  every  patient  should  be  treated.
23,24  Some  neurologists  begin 
treatment in patients with a clinically isolated syndrome and two or more clinically silent 
lesions suspect for MS on the brain MRI.
24 Others do not treat patients at the time of 
diagnosis because there is a chance for a benign disease course.
5 The high price, adverse 
effects and unproven long-term efficacy of immunomodulatory drugs for MS are reasons 
to  refrain  from  immediate  treatment.  In  our  hospital  we  always  discuss  the  option  of 
immunomodulatory treatment with our patients and many patients decide not to use it.  
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Immunomodulatory therapies do, however, prevent new T2 lesions and the enlargement of 
existing T2 lesions. In view of our results, this effect of immunomodulatory drugs may be 
a worthwhile therapeutic goal. 
 
Our results suggest that the extent of base-line T2 lesions, and their development over 
time,  should  be  taken  into  consideration  when  therapeutic  decisions  in  patients  with 
relapsing-remitting MS are made. 
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Abstract 
 
To assess the predictive value of T2 lesions on the rate of progression of disability in 
multiple sclerosis (MS), we reanalyzed T2 lesion number and load on brain MRI scans 
performed before 1997 of 186 MS patients, who were clinically followed. There were 90 
patients with progressive MS (35 secondary progressive and 55 primary progressive), and 
96 with relapsing remitting MS. The rate of progression of disability was measured by the 
Multiple Sclerosis Severity Scale (MSSS), and by time to progression of disability (defined 
as an increase in ≥ 1 point when the EDSS was 5.5 or less and an increase in EDSS of ≥ 
0.5 point when the EDSS was 6.0 or higher). During follow-up (median 15 years, IQR 12 – 
17 years) 94% of the patients with progressive MS and 50% of the patients with relapsing 
remitting  MS  had  progression  of  disability.  Higher  T2  lesion  number  and  load  were 
associated with a higher rate of disease progression on the MSSS and a shorter time to 
progression  of  disability  in  relapsing  remitting  MS,  but  not  in  progressive  MS.  Our 
findings indicate that the amount of T2 lesions has a small predictive value for progression 
of disability in relapsing remitting MS, but has no influence on the rate of progression in 
progressive MS. 
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Introduction 
 
Inflammation in white matter tracts of the central nervous system (CNS) is responsible for 
the relapses in patients with multiple sclerosis (MS).
1 Twenty years after the first symptom 
around  70%  of  the  patients  with  a  relapsing  remitting  disease  course  have  gradual 
progression  of  their  symptoms,  which  is  termed  secondary  progressive  MS.
2,3  Ten  to 
twenty percent of MS patients experience a gradual progression of symptoms from the 
onset of their disease, which is called primary progressive MS. Both the secondary and 
primary progressive phase of MS is caused by a slowly progressive axonal degeneration. 
Predicting the rate of progression of disability in an individual MS patient is difficult on 
clinical grounds.
4,5 In patients with clinically isolated syndromes, a higher number of T2 
lesions, which can represent current or past episodes of inflammation, is associated with a 
more  severe  disease  course.
6,7,8  Previously,  we  have  shown  in  patients  with  relapsing 
remitting  MS  that  a  higher  number  of  T2  lesions  is  associated  with  a  higher  risk  of 
becoming secondary progressive.
9 Since epidemiological and pathological studies, as well 
as clinical trials with immunomodulatory and immunosuppressive drugs, indicate that the 
progressive  phase  of  MS  runs  quite  independently  from  inflammation,
3,10,11,12,13  we 
interpreted  this  association  as  an  earlier  clinical  expression  of  the  ongoing  axonal 
degeneration  due  to  a  decreased  CNS  reserve  capacity.
9  However,  in  view  of  this 
hypothesis, we would also expect an effect of the amount of T2 lesions on the rate of 
progression of disability in patients with progressive MS. 
The aim of this study was to investigate the influence of T2 lesion number and load on the 
rate of progression of disability in patients with relapsing remitting and progressive MS.  
 
Methods 
 
Patients 
The Groningen MS database was established in 1985. Data from all patients attending the 
Groningen MS clinic are systematically entered in the database at first visit and after each 
follow-up  visit  (at  regular  intervals  between  3  and  12  months).  We  retrospectively 
collected the available cerebral MRI scans of all MS patients performed between 1987 
(installation of the first MRI scanner in Groningen) and 1997.   
Disability was measured with the Expanded Disability Status Scale (EDSS; scores range 
from 0 to 10 with higher scores indicating more disability).
14 Progression of disability was 
defined as an increase in ≥ 1 point when the EDSS at scanning was 5.5 or less and as an 
increase in EDSS of ≥ 0.5 point when the EDSS at scanning was 6.0 or higher. This 
definition  is  commonly  used  in  clinical  trials  evaluating  effects  of  medication  in  the 
progressive phase of the disease.
15,16,17    84 
Rate of progression of disability was measured with time to progression of disability (in 
years) and with Multiple Sclerosis Severity Scale (MSSS).
18 This score is based on the 
combination  of  EDSS  and  disease  duration,  and  ranges  from  0  to  10.  Higher  scores 
indicate a faster progression of disability. The MSSS was calculated at time of scanning 
and at last follow-up. 
A progressive disease course (primary or secondary) was defined as a slowly progressive 
neurological worsening for at least 12 months. EDSS, disease duration and age at time of 
scanning, gender, time to progression (in years), and use of immunomodulating therapy 
(either interferon beta or glatiramer acetate; duration of therapy) were extracted from the 
database. 
MRI 
MRI was performed on a 1.5 Tesla scanner (Philips Gyroscan S15) in 179 patients and on a 
1.0 Tesla scanner (Magneton Expert) in 7 patients. Slice thickness was 5 mm in most 
patients (n=126), and 3, 6, 7, 9 and 10 mm in the remainder (1, 8, 1, 11 and 39 patients, 
respectively).  The  hardcopies  of  all  scans  were  analyzed  by  an  experienced 
neuroradiologist (J.C. de G.), who was unaware of the clinical data. Lesions were classified 
by region (supratentorial, infratentorial) and by size (small < 5mm; medium 5 – 10 mm; 
large >10 mm, or confluent). Confluent lesions were defined as single T2 lesions larger 
than 20 mm typically located in the periventricular region, or as two or more T2 lesions 
connected at one or more margins.
19 We estimated the total lesion volume by assuming the 
lesions were spherical with a fixed diameter size per category as described previously.
20  
 
Statistical analyses 
To estimate the predictive value of brain MRI findings on progression of disability, we 
performed Cox proportional-hazards regression analyses to calculate hazard ratios with 
adjustment for age at time of scanning, disease duration at time of scanning, EDSS at time 
of  scanning,  and  gender.  We  analysed  the  relapsing  remitting  and  progressive  disease 
courses  separately.  T2  lesion  number  and  T2  lesion  load  were  entered  as  continuous 
variables. We also studied the presence of confluent lesions and infratentorial lesions. The 
time-to-event was the time between the MRI scan and progression of disability or to the 
date of the last follow-up visit if progression had not developed.  
Between  group  comparisons  were  analyzed  using  Mann-Whitney  tests,  Kruskal-Wallis 
tests or Chi-Square tests where appropriate. Correlation coefficients were calculated with 
Spearman’s rank correlation test. Significance was taken at a p value < 0.05. All analyses 
were  performed  with  the  Statistical  Package  for  the  Social  Sciences  (SPSS  14.0  for 
Windows, SPSS Inc., Chicago, Illinois, USA). 
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Results 
 
Patients 
The  MRI  scans  of  200  patients  were  available  for  analysis.  Fourteen  patients  were 
excluded because no T2 scan was available (n=4) or follow-up was lacking (n=10). The 
characteristics of the remaining 186 patients are shown in table 1. During a median follow-
up time of 15 years, 134 patients had progression of disability. Compared to patients with 
PPMS, patients with SPMS were younger at the time of their first MRI scan (p=0.033), had 
longer disease duration (p=0.006) and experienced more disability as measured with the 
EDSS  (p=0.014).  Of  the  96  patients  with  relapsing  remitting  MS,  48  (50%)  had 
progression of disability.  
  
Table 1 Characteristics of the participating patients (median, IQR). 
Characteristics  All patients  Relapsing 
Remitting 
Secondary 
Progressive  
Primary 
Progressive  
Number of patients  186  96  35  55 
Gender: male (%)/ female 
(%) 
62 (33%)/ 124 
(67%) 
29 (30%) / 67 
(70%) 
15 (43%) / 20 
(57%) 
18 (32%) / 37 
(67%) 
Age at time of the MRI 
scan (years) 
39 (31 – 48)  34 (27 – 41)  41 (32 – 49)  48 (39 – 55) 
Disease duration at time of 
scanning (years) 
4 (1 – 9)  2 (0 – 7)  10 (3 – 21)  4 (2 – 9) 
Follow-up after the MRI 
scan (years) 
15 (12 – 17)  15 (13 – 17)  15 (10 – 18)  15 (11 – 18) 
EDSS at time of scanning  3.0 (2.0 – 4.5)  2.0 (1.0 – 2.5)  5.0 (4.0 – 6.0)  4.0 (3.0 – 6.0) 
EDSS at last follow-up  6.0 (3.0 – 7.5)  3.3 (2.0 –6.0)  7.5 (7.0 – 9.0)  6.5 (6.0 – 8.0) 
MSSS at time of scanning  5.8 (3.3 – 8.0)  4.3 (2.4 – 6.1)  6.9 (5.1 – 8.8)  7.7 (5.9 – 8.6) 
MSSS at last follow-up  5.6 (2.2 – 8.2)  2.3 (1.0 – 5.3)  8.0 (6.7 – 9.9)  7.5 (5.7 – 9.5) 
Progression of disability 
during follow-up: N (%) 
134 (72%)  48 (50%)  33 (94%)  52 (95%) 
Time to progression (years)  3 (1 – 5)  3 (2 – 7)  2 (1 – 4)   3 (2 – 5)  
  
 
Brain MRI 
Double  reading  was  performed  for  a  random  set  of  24  scans.  Intra-class  correlation 
coefficients were excellent or good for T2 lesion load (r = 0.96; p < 0.001) and T2 lesion 
number (r = 0.95; p < 0.001).  
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Table 2 MRI characteristics of the participating patients (median, IQR). 
Characteristics  All patients  Relapsing 
Remitting 
Secondary 
Progressive  
Primary 
Progressive  
Number of patients  186  96  35  55 
T2 lesion load (ml)  2.0 (0.4 – 4.5)  1.5 (0.3 – 3.7)  4.1 (1.2 – 6.0)  1.8 (0.3 – 4.5) 
Total number of T2 lesions  11 (5 – 24)  9 (4 – 19)  20 (10 – 38)  13 (4 – 26) 
Confluent lesions: yes  
Number (%) 
51 (27%)  26 (27%)  10 (29%)  15 (27%) 
Infratentorial lesions: yes  
Number (%)*  
28 (16%)  13 (14%)  10 (29%)  5 (10%) 
* N=177 
 
MRI characteristics of all patients and per disease course are presented in table 2.  
Compared to patients with PPMS, those with SPMS had a higher T2 lesion load (p=0.011), 
higher T2 lesion number (p=0.034), and more frequent infratentorial lesions (p=0.02). 
In relapsing remitting MS the 48 patients with progression of disability had a slightly 
higher T2 lesion load compared to the 48 patients with no progression of disability (median 
2.4 ml versus 1.3 ml, p = 0.06). The follow-up time was similar (median of 15 years in 
both groups). 
 
Influence of T2 lesions on the rate of progression of disability 
In patients with relapsing remitting MS, but not with progressive MS, T2 lesion load and 
T2 lesion number correlated with the MSSS at follow-up (table 3).  
 
Table 3 Correlations of T2 lesion load and T2 lesion number with MSSS scores. 
    MSSS at scanning  MSSS at last follow-up 
PMS  T2 lesion load  0.06  0.19 
  T2 lesion number  0.04  0.04 
RRMS  T2 lesion load  0.02  0.29# 
  T2 lesion number  0.10  0.32# 
# p < 0.01; PMS = progressive MS; RRMS = relapsing remitting MS. 
 
In relapsing remitting patients a higher number of T2 lesions, a higher T2 lesion load and 
the presence of confluent lesions increased the risk of progression of disability (table 4). 
No other clinical variable predicted the time to progression of disability (all p-values > 
0.24). In contrast, in patients with progressive MS, MRI and clinical variables did not 
predict progression of disability (table 5).  
Analysis of PPMS and SPMS separately did not show any significant correlation with 
MSSS and any significant predictor for progression of disability either (data not shown). 
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Table 4 Cox regression analyses for progression of disability of the separate MRI variables 
in patients with relapsing remitting MS controlled for EDSS at time of scanning, age at 
time of scanning, disease duration at time of scanning and gender. 
Variable    Hazard Ratio  95% CI  p-value 
T2 lesion load   per ml increase  1.16  1.06 – 1.26  0.001 
T2 lesion number  per number 
increase  
1.02  1.003 – 1.03  0.026 
Confluent lesions   No  1.0 (reference)     
   Yes  2.58  1.41 – 4.73  0.002 
Infratentorial lesions  No  1.0 (reference)     
  Yes  0.72  0.27 – 1.90  0.51 
 
Table 5 Cox regression analyses for progression of disability of the separate MRI variables 
in patients with progressive MS controlled for EDSS at time of scanning, age at time of 
scanning, disease duration at time of scanning and gender. 
Variable    Hazard Ratio  95% CI  p-value 
T2 lesion load   per ml increase  1.01  0.94 – 1.08  0.84 
T2 lesion number  per number 
increaese 
1.002  0.99 – 1.011  0.73 
Confluent lesions   No  1.0 (reference)     
   Yes  1.16  0.69 – 1.95  0.58 
Infratentorial lesions  No  1.0 (reference)     
  Yes  1.21  0.65 – 2.27  0.53 
 
 
Influence of immunomodulating treatment on progression of disability 
Five patients with secondary progressive MS (mean time of treatment 5 years, sd 1.9), 3 
patients with primary progressive MS (mean time of treatment 4 years, sd 1), and 23 out of 
the 96 (24%) patients with relapsing remitting MS received interferon-beta (mean time of 
treatment: 7.13 years, sd 3.4). Only 8 patients received immunomodulating therapy before 
progression of disability had occurred. In the other patients progression of disability was 
the  reason  for  starting  treatment.  The  numbers  were  too  low  to  evaluate  the  effect  of 
immunomodulating therapy on the time to progression of disability.  
In patients with relapsing remitting MS MSSS scores at last follow-up were higher in 
patients who had used immunomodulating therapy compared to patients that had not (mean 
4.5 and 3.0 respectively, p = 0.009).  This difference was not found for patients with 
progressive MS.    88 
Discussion 
 
In relapsing remitting patients a higher T2 lesion load and number increased the risk for 
earlier and faster progression of disability. In contrast, we found no relationship between 
the amount of T2 lesions and rate of progression of disability in patients with progressive 
forms of MS.  
 
T2  lesions  represent  a  diverse  pathological  substrate,  ranging  from  blood-brain  barrier 
breakdown and inflammatory demyelination to fibrillary astrocytosis and remyelination.
21 
T2  lesions  are  considered  to  result  from  inflammatory  disease  activity,  whereas 
progression in progressive forms of MS is caused by relentless axonal degeneration. The 
lack of a relation between T2 lesion load and number on progression of disability in the 
progressive phase indicates that this process of axonal degeneration is largely independent 
from the focal inflammatory disease activity. This is in agreement with several studies 
showing a lack of effect of immunomodulatory and immunosuppressive treatment on the 
progressive phase of the disease,
3 lack of an association between the number of clinical 
relapses and progression,
10 and a dissociation of axonal loss from lesion load in patients 
with early multiple sclerosis.
11 
 
The  predictive  value  of  T2  lesions  for  progression  of  disability  in  relapsing  remitting 
patients  is  in  agreement  with  follow-up  studies  of  different  cohorts  of  patients  with 
clinically isolated syndromes showing a higher level of disability after 5 years, 13 years 
and 20 years of follow-up in patients with more T2 lesions at baseline MRI.
6,7,8 It also 
supports our finding that more T2 lesions in relapsing remitting MS are associated with a 
higher  risk  of  becoming  secondary  progressive.
9  It  is  important  to  mention  that  the 
predictive value of T2 lesions for progression of disability in relapsing remitting MS is 
modest and not absolute.
6,22 
 
How can we explain that T2 lesions predict progression of disability in relapsing remitting 
MS but not in progressive MS? In RRMS progression of disability is mainly caused by 
axonal injury in the context of focal inflammatory demyelination. Assuming that every MS 
patient has a gradual progressive axonal degeneration and that every MS patient has some 
clinically silent inflammatory demyelination, decreased CNS reserve capacity due to more 
T2 lesions can lead to an earlier clinical expression of progression of disability.
9 Once 
patients have reached a critical threshold of axonal degeneration, they enter the progressive 
phase of the disease, and from that time the rate of subsequent progression is no longer 
influenced by the existing reduction in reserve capacity.
23  
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The main strength of this study is the fact that we have a large cohort of patients with well-
documented clinical follow-up. Since we used Cox-regression models we could include all 
patients with an available MRI-scan and at least one year of follow-up. Limitations of our 
study were the lack of follow-up MRI-scans, and the difference in slice thickness and MR 
field  strength  between  the  scans.  The  EDSS  has  many  limitations,  like  a  poor 
reproducibility and a tendency to measure mainly pyramidal dysfunction, especially in its 
higher ranges. Nevertheless, the EDSS is the most frequently used scale to assess disability 
and alternative scales are currently lacking. 
The MSSS is a scale derived from the EDSS with a correction for disease duration. It is 
relatively unreliable in the first two years of the disease,
18 which might explain the lack of 
a relationship between the amount of T2 lesions and MSSS at time of scanning in relapsing 
remitting  MS.  The  similar  results  of  the  time  to  progression  of  disability  and  MSSS 
analyses provide further support that the MSSS is suitable to measure rate of progression 
of disability in MS. 
 
Studies with follow-up measurements of T2 lesion load should be performed to further 
investigate whether changes in the amount of T2 lesion load over time are associated with 
progression of disability in progressive MS.  
 
Our study is of pathophysiological interest and may have practical implications with regard 
to counselling, in so far that the amount of T2 lesions is a prognostic factor for progression 
of disability in relapsing remitting MS, but seems to have no prognostic significance in the 
progressive forms of MS. 
   90 
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Abstract 
Animal  experiments  suggest  that  astrocytic  glycogen  may  act  as  an  energy  source  for 
axons especially during heightened activity. In this model astrocytic glycogen breaks down 
to lactate that is shuttled to axons where it is metabolised oxidatively to generate ATP. The 
aim of this study was to investigate whether 
1H-magnetic resonance spectroscopy could be 
used  to  detect  a  rise  in  lactate  levels  in  human  white  matter  during  enhanced  axonal 
activation.  Six  healthy  volunteers  (4  women  and  2  men;  age  range  21-38  years) 
participated in the study. We were unable to detect any significant MR spectral change, i.e. 
neither in the peak areas of inositol, choline, creatine, glutamate and N-acetylaspartate nor 
in the lactate level, in the contralateral posterior limb of the internal capsule during intense 
motor activation of the hand (4 successive episodes of squeezing a soft ball for 7 minutes 
followed  by  7  min  rest).  Possible  explanations  are  that  the  technique  is  not  sensitive 
enough to detect a small rise in lactate, or lactate turnover is too fast to be detected, or that 
another  monocarboxylate  different  from  lactate  may  be  involved  in  axonal  energy 
metabolism.   
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Introduction 
 
Lactate produced by the breakdown of glycogen in astrocytes plays an important role in 
energy metabolism of axons, especially during increased physiological activity.
1,2 With in 
vivo 
1H magnetic resonance spectroscopy (MRS) of the human brain we have detected 
lactate in pathological conditions such as cancer.
3 With exception of a phenomenon not 
uncommon with aging beyond 60 years,
4 healthy persons do not have brain tissue lactate 
levels beyond a level of 0.5 mM, generally considered to be the MRS detection limit. A 
number  of  studies  with  magnetic  resonance  spectroscopy  (MRS)  in  human  volunteers 
claim  to  have  detected  transient  increases  in  lactate  levels  in  the  relevant  brain  areas 
following either motor, visual, auditory or cognitive stimulation.
5,6,7,8,9,10,11,12  
Because axons can extend over great distances from their cell bodies, they depend on local 
production  of  ATP  to  maintain  ion  gradients  and  sustain  other  energy-consuming 
functions, such as axonal transport. Along axons in the white matter, astrocytes extend 
processes that directly abut nodes of Ranvier where axonal energy metabolism primarily 
takes place.
13 Astrocytic glycogen is converted to glucose phosphate, and then via pyruvate 
to  lactate,  which  is  released  in  the  extracellular  space.  In  this  model,  the  astrocyte  to 
neuron lactate shuttle hypothesis based on studies of murine cells,
14 astrocytes produce 
lactate in response to synaptically released glutamate. Lactate can be taken up by neurons 
through monocarboxylate transporters and then converted to pyruvate. Pyruvate enters the 
mitochondria where it is metabolized via the oxidative metabolism to generate ATP.
1,2 The 
purpose of this investigation was to use 
1H MRS to evaluate motor stimulus-dependent 
changes in lactate level, and in the other MRS detectable metabolites (inositol, choline, 
creatine, glutamate and N-acetylaspartate), in human white matter.  
 
Methods 
 
Six  right-handed  healthy  volunteers  (4  women  and  2  men;  age  range  21-38  years) 
participated.  The  ethical  committee  of  the  Academic  Hospital  Groningen  approved  the 
project and all subjects signed an informed consent paper before participation. All scans 
were performed at 1.5 Tesla. Automated hybrid PRESS (point resolved spectroscopy) 2D-
chemical shift imaging (CSI) measurements with a repetition time (RT) of 1500 ms and an 
echo time of  135 ms  were performed.  Hybrid-CSI includes  pre-selection  of a volume  of 
interest  (VOI)  that  is  located  within  the  brain  to  prevent  the  strong  interference  from 
subcutaneous fat and is smaller than the phase-encode field of view (FOV) that must be large 
enough to prevent wraparound artefacts.
15  
The CSI sequence produced a 16x16 transversely oriented matrix that was defined by phase 
encoding with a FOV of varying dimensions to allow for optimal measurement in the posterior 
limb of the internal capsule (Figure 1A). The field homogeneity achieved in automated non-  98 
localized multiple angle projection (MAP) shimming resulted in water peak line widths of less 
than 8 Hz in the VOI. Excitation with with 2.56 ms sinc-Hanning shaped radio frequency (RF) 
pulses preceded by 25.6 ms Gaussian shaped RF pulses for chemical shift selective excitation 
(CHESS) and subsequent spoiling of the resultant water signal, was followed by collection of 
the second spin echo using 1024 data points and a spectral width of 500 Hz. All 16x16 2D-CSI 
measurements were 1 acquisition per phase encoded step with 4 pre-scans and RTs of 1500 ms 
(acquisition time 7 min). Time domain data were multiplied with a Gaussian function (center 0 
ms, half width 256 ms), 2D-Fourier transformed, phase and baseline corrected and quantified 
by means of frequency domain curve fitting with the assumption of Gaussian line shapes, 
using the standard "Numaris-3" software package provided with the MR system. Sixth order 
polinomial lines with a 0-4.3 ppm calculation range were used for baseline correction. In the 
curve fitting the number of peaks fitted included the chemical shift ranges restricted to 3.4-3.6 
ppm for inositol, 3.1-3.3 ppm for choline (Cho), 2.9-3.1 for creatine (Cr), 2.2-2.4 for glutamate 
(Glu), 1.9-2.1 for N-acetylaspartate (NAA), and 1.2-1.5 ppm for lactate, and their line widths 
and peak intensities unrestricted. We acknowledge that inositol and Glu are best detected at 
TE’s shorter than the 135 ms used here and that in our case one might fail to detect a small 
change in the level of these particular metabolites. Part of our TE-135 ms CSI measurements 
was therefore repeated at TE 40 ms. Using standard post-processing protocols the raw data 
were thus processed automatically, allowing for operator-independent quantifications.  
In all subjects a T2 weighted MRI series was used as guidance for defining the volume of 
interest for MRS. The VOI typically was a transversely oriented volume of approximately 
8x8x2 cm3, phase encoded into 64 voxels of 2 cm3 each, extending over both hemispheres 
and including 24 voxels containing caudate nucleus, posterior limb of the internal capsule, 
putamen and thalamus (Figure 1C and D). The MRS measurements were performed at rest 
(7 min) and subsequently while the subject was squeezing a soft ball at a frequency of 
1/1.5sec with the dominant right hand for 7 min. A total of 4 successive measurements at 
rest and during activation were performed. The investigator verified that hand squeezing 
was performed correctly.  
 
Results 
 
A representative example of MRS measurements is shown in Figure 1B. No lactate was 
detected either in rest or during right hand motor stimulation in any of the 12 voxels shown 
in Figure 1C and D. No significant differences in other metabolites (inositol, Glu, NAA, 
Cr, Cho) were found between the resting state and during motor activation. Upon repeating 
part of our TE-135 ms CSI measurements at TE 40 ms we still failed to detect any lactate 
or any change in the peak areas of inositol and Glu, compounds with comparatively short 
T2’s and thus more accurately quantified at shorter TE, during motor activation. Table 1 
illustrates that at motoric activation the levels of Cr and NAA are not affected. The trend of 
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comparative Cho decrease on the contralateral (=left) side is not significant, neither is any 
change in any MRS voxel when considered separately.  
 
 
 
Figure 1 
1H-magnetic resonance spectroscopy. CSI performed at TE=135ms yields a map 
of 64 spectra (A) showing peaks of  Cho, Cr, Glu and NAA (B). The white arrow points to 
the spectrum where lactate should appear.  Only some noice is seen. Below are 12 spectra 
containing caudate nucleus (c), posterior limb of the internal capsule (i), putamen (p), and 
thalamus (t), of the left (C) and right (D) hemisphere.  
 
 
Table 1 Metabolite peak areas at right hand motor activation, in % of the areas at rest 
±SEM, in two volumes in the left and right brain hemisphere containing capsula/caudate 
nucleus/putamen. 
    Cho  Cr  NAA  Lactate 
Left (sum of 12 
voxels=24 ml) 
 
  98±5 
 
 100±7 
 
  99±7 
 
 _____* 
Right (sum of 12 
voxels=24 ml 
 
103±4 
 
 
100±5 
 
 
 99±7 
 
 
 _____* 
 
Total VOI (64 
voxels) 
 
103±4 
 
100±5 
 
 99±5 
 
 _____* 
*Not detected   100 
Discussion 
 
There are a number of possible explanations why we were unable to detect an activation-
induced increase in lactate levels in the corticospinal tract at the level of the posterior limb 
of the internal capsule. First, the theory concerning lactate as energy resource for axons 
may be wrong. Brown and colleagues found that intense neural activity reduced glycogen 
content in adult mouse optic nerve, a prototypic white matter preparation.
1 Axon function 
was quantified by measuring the compound action potential (CAP) area. The CAP declined 
more  rapidly  during  high  frequency  stimulation  if  monocarboxylate  transport  out  of 
astrocytes or into axons was inhibited. Although most probably lactate, the exact nature of 
the  monocarboxyate  has  not  been  demonstrated  with  certainty.  Thus,  another 
monocarboxyate might be involved. Second, lactate buildup is not a necessary condition of 
the astrocyte to neuron lactate shuttle hypothesis. In fact the key event leading to glycogen 
breakdown may be a fall in baseline lactate precipitated by increased axonal lactate uptake 
as local glucose is depleted. This event may be ‘sensed’ by neighboring astrocytes which 
would then increase their lactate export through glycogen breakdown. The sum of these 
shifts might not increase measurable lactate concentration. Third, the motor stimulus may 
have been inadequate. This may be true, although in our experiment the motor activity was 
much stronger than in the previous MRS study of motor activation by Kuwabari and co-
workers  who  reported  a  rise  in  lactate  in  the  basal  ganglia  (putamen,  globus  pallidus) 
following finger opposition movements.
6 Fourth, lactate produced by astrocytes is readily 
converted into pyruvate and oxidatively metabolised and cannot be detected because it 
does not accumulate.  
To our knowledge the above mentioned study of Kuwabari is the only published MRS 
study of motoric activation. The claim of lactate increases in the basal ganglia brain region 
following finger opposition movements is not reproduced in our study in which a much 
stronger stimulus was applied. Our failure to detect true lactate does not reflect inadequate 
sensitivity of the MRI equipment used in this study; to the contrary, in terms of signal–to-
noise ratio and resolution the spectra shown here (Fig.1) are not inferior to those published 
by others. Considering the appearance of the “Lactate” in the spectrum shown in reference 
6,  it  appears  likely  that  artefacts,  such  as  out-of-phase  lipid  signals,  were  erroneously 
interpreted as lactate. In a recent  paper we have shown how out of phase lipid signals from 
outside the VOI are easily mistaken for lactate.
16 An other explanation for the discrepancy 
is partial volue effect due to the substantial ventricular space included in the large MRS 
voxels measured by Kuwabara et al
6; whereas in normal brain tissue the lactate levels are 
in the order of 0.3 mM and up to a couple of mMs in severe hypoxia or pathology, in 
cerebrospinal fluid the lactate level can easily be even higher as well as more visible in the 
MR spectrum because of a longer T2 relaxation time.
17 Although in our study we zoomed 
in on the motoric activity brain areas with a spatial resolution of 2 cm
2, this may still have 
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been too crude for being able to detect the metabolism in the corticospinal tracts involved. 
A (maybe still optimistic) filling of the relevant MRS voxels by 10% with the corticospinal 
tracts involved with hand movement would require a tract lactate level of 10 x 0.5 mM = 5 
mM to yield a clear lactate level in the MR spectrum.   
The trend of comparative contralateral (= left side) Cho decrease upon (right hand) motoric 
stimulation, though not significant and unexplained, resembles the trends of Cho decrease 
observed recently in occipital brain tissue upon optic stimulation.
16  
In conclusion, MRS of the internal capsule in humans is not a suitable method for studying 
the so-called lactate shuttle from astrocytes to axons during physiologic activation of the 
corticospinal tract. With the use of  higher field MRS eqiupment (3T or higher) it might be 
possible to detect any subtle changes in lactate level that might happen in the concentration 
range up to 0.5 mM (or higher if one takes partial volume effects into account).   102 
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Abstract 
 
N-acetylaspartate  /  creatine  (NAA/Cr)  ratios,  assessed  with  proton  magnetic  resonance 
spectroscopy,  are  increasingly  used  as  a  surrogate  marker  for  axonal  dysfunction  and 
degeneration in multiple sclerosis (MS). The purpose of this study was to test short-time 
reproducibility of NAA/Cr ratios in patients with clinically stable MS. 
In 35 MS patients we analysed NAA/Cr ratios obtained with 
1H-MR spectroscopic imaging 
at the centrum semiovale either with lateral ventricles partially included (group 1; n=15) or 
more  cranially  with  no  ventricles  included  (group  2;  n=20).  To  test  short-term 
reproducibility of the NAA/Cr measurements, patients were scanned twice 4 weeks apart. 
We determined mean NAA/Cr and Cho/Cr ratios of 12 grey matter and 24 white matter 
voxels.  
Mean NAA/Cr ratios of both the white and grey matter did not change after 4 weeks. 
Overall  four  week  reproducibility  of  the  NAA/Cr  ratio,  expressed  as  coefficient  of 
variation,  was  4.8  %  for  grey  matter  and  3.5  %  for  white  matter.  Reproducibility  of 
scanning  cranially  of  the  ventricles  was  slightly  better  than  with  cerebrospinal  fluid 
included. 
Our study shows good short-term reproducibility of NAA/Cr ratio measurements in the 
centrum semiovale, which supports the reliability of this technique for longitudinal studies. 
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Introduction 
 
Multiple  sclerosis  (MS)  is  a  chronic  disorder  of  the  central  nervous  system  with 
inflammatory demyelination and axonal degeneration.
1 The disease usually starts between 
the ages of 20 and 40 years, and by the age of 55 years, about half of the patients needs 
unilateral assistance to walk.
2 The disease progresses slowly and clinical scales currently 
used  are  not  sensitive  enough  to  quantify  progression.
3  Using  surrogate  markers  of 
progression can shorten the duration of clinical trials in progressive MS.  
 
¹H-magnetic  resonance  spectroscopy  (¹H-MRS)  of  the  brain  in  MS  patients  can  detect 
changes  in  cell  metabolites  in  both  focal  lesions  and  normal  appearing  white  matter 
(NAWM).
4  Compared to controls, N-acetylaspartate (NAA) concentrations in MS patients 
are lower both in the lesions and in NAWM, whereas creatine (Cr) concentrations are equal 
to  slightly  increased.
5  NAA  is  a  marker  of  neuroaxonal  metabolism  and  integrity,  and 
reductions in the white matter are due to axonal dysfunction or loss. It has been suggested 
that whole brain NAA decline rates in patients with MS may predict future disease course.
6 
Cr is present in neurons, astrocytes and oligodendrocytes, and elevations in white matter of 
MS patients can be due to axonal transection, astrocytic proliferation, and demyelination. 
Because absolute concentrations of metabolites with ¹H-MRS are difficult to interpret, the 
NAA/Cr  ratio  is  often  used  as  a  valid  surrogate  marker  of  ‘cerebral  tissue  integrity’.
5 
Decreases  in  NAA/Cr,  which  in  MS  patients  are  found  in  lesions  and  NAWM,  are 
indicative  of  neuroaxonal  disturbance,  oligodendroglial  disturbance,  or  astrocytic 
proliferation.  The third metabolite well observable in long TE ¹H-MRS is Choline (Cho) 
which is regarded as a marker of glial proliferation.
7 
 
Next to validity, good surrogate markers need to be reliable, especially when used for 
monitoring white matter integrity in longitudinal studies. In this study we investigated the 
reproducibility of NAA/Cr ratios obtained with 2D spectroscopic imaging at two different 
levels of the centrum semiovale within a time span of 4 weeks in patients with clinically 
stable MS. 
 
Methods 
 
Patients 
All  patients  co-operated  in  the  study  with  informed  consent  and  local  medical  ethical 
committee approval. Thirty-five patients participated in the study. Patients were randomly 
divided in two groups. All patients had clinically definitive MS  with a relapsing remitting 
or  secondary  progressive  disease  course.
8,9  None  of  the  patients  were  using 
immunomodulatory medication. Patients were relapse free for at least 4 weeks and had not   108 
taken corticosteroids 4 weeks prior to the first MRI and during the study period. Disability 
was  assessed  with  the  Expanded  Disability  Status  Scale  (EDSS),  which  gives  a  score 
ranging from 0 to 10 with higher scores indicating more disability.
10  
 
1H-MR Spectroscopy  
MRI scans of the brain were obtained at baseline and after 4 weeks at a 3.0 Tesla unit 
(Philips,  Best,  The  Netherlands). 
1H-MR  spectroscopic  imaging  was  preceded  by  the 
acquisition of a transverse multiple slice MRI series in order to position the volume of 
interest (VOI). The standard transmitter/receive coil was used and the volume localisation 
was done by a combination of slice selection and 2D phase encoding with outer volume 
suppression with 12 rest slabs. All scan parameters were the same: TE=144 ms, TR=2.5s, 
FOV=230mm, slice thickness=20mm, matrix= 24x24, turbo factor=3. Total scan time was 
around 8 minutes. 
         
 
Figure 1 Sagittal MRI image showing the 
volume of interest scannedin grop 1 (A) and 
group 2 (B) with an axial image (C) 
displaying the grey (inner 12) and white 
matter (outer 12 in both hemispheres) voxels. 
Chapter 8 Chapter 8 
  109 
Group 1 was scanned around the lateral ventricles with some cerebrospinal fluid included 
in  the  VOI  (figure  1A).  Group  2  was  scanned  above  the  lateral  ventricles  with  no 
cerebrospinal fluid included in VOI (figure 1B). Individual anatomic landmarks were used 
for voxel repositioning. 
To select voxels that mainly contained grey matter 12 spectroscopic imaging (SI) voxels 
were selected in the midline grey matter in each subject (figure 1C). To select voxels that 
mainly contained white matter 24 SI voxels were selected (12 in each hemisphere) in the 
deep white matter in each subject (figure 1C). Metabolite peak areas of NAA and Cho 
were  determined  with  the  manufacturers  software  (Philips  SPECTROVIEW)  and  are 
expressed as ratios to Cr. All voxels were visually checked for quality of the spectra and 
quality of the fitting of the peak areas and rejected if inaccurate according to the opinion of 
the two observers. 
In every patient the NAA/Cr and Cho/Cr ratios per voxel were determined and average 
ratios of the voxels in grey and white matter were calculated. 
 
Statistical analysis 
Reproducibility was tested by a coefficient of variation (CV = 100 * standard deviation of 
the mean difference / [√2 * pooled mean values]).
11 Changes in grey matter and white 
matter after 4 weeks and differences between baseline grey and white matter NAA/Cr 
ratios in patients were tested with paired t-tests. Differences between baseline grey matter 
and white matter NAA/Cr ratios of the 2 VOIs were tested with unpaired t-tests. 
 
Results 
 
Baseline characteristics of the patients are shown in table 1.  
 
Table 1 Characteristics of the patients.  
 
All  Group 1  Group 2 
Number  35  15  20 
Gender: Male   16 (46%)  8 (53%)  8 (40%) 
Disease course: Relapsing 
Remitting / Secondary 
Progressive 
31 / 4  13 / 2  18 / 2 
Age: mean (sd) in years  40 (9)  43 (10)  37 (8) 
Disease Duration: mean (sd) 
in years 
11 (7)  12 (9)  11 (6) 
EDSS: median (IQR)  3.0 (1.5 – 4.0)  3.0 (1.5 – 4.5)  3.0 (2.0 – 4.0) 
sd = standard deviation; IQR = interquartile range   110 
Patients were scanned after a mean ± standard deviation of 27.3 ± 2.2 days. The mean 
number of excluded voxels was 1.51 ± 2.93 for NAA/Cr and 4.54 ± 5.40 for Cho/Cr (out of 
36 voxels). White matter NAA/Cr and Cho/Cr ratios were higher than grey matter ratios 
(table 2). The mean NAA/Cr did not change in either white matter or grey matter in both 
groups after 4 weeks (table 2).  
 
Table 2 The NAA/Cr ratios in the centrum semiovale at week 0 and week 4: Mean (sd). 
    Week 0  Week 4  p- value
* 
All   NAA/Cr white matter   2.27 (0.26)  2.26 (0.25)  0.60 
(N=35)  NAA/Cr grey matter    1.90 (0.23)
 #  1.88 (0.21)  0.42 
  Cho/Cr white matter  1.05 (0.13)  1.03 (0.15)  0.11 
  Cho/Cr grey matter  0.98 (0.12)
 #  0.98 (0.13)  0.60 
Group 1   NAA/Cr white matter  2.45 (0.26)  2.45 (0.25)  0.82 
(N=15)    NAA/Cr grey matter  2.08 (0.23) 
#  2.03 (0.20)  0.30 
Group 2   NAA/Cr white matter  2.14 (0.15)
  2.13 (0.14)  0.53 
(N=20)  NAA/Cr grey matter:    1.76 (0.11)
 #  1.77 (0.12)  0.87 
* p- value: comparison week 0 with week 4 
# p < 0.001: comparison grey matter with white matter 
sd = standard deviation 
 
The NAA/Cr ratios in grey and white matter were significantly higher in the group scanned 
with the ventricles partially included (p < 0.001). Mean Cho/Cr in white and grey matter 
was 1.14 and 1.07 in group 1 and 0.98 and 0.92 in group 2 (p<0.001). Overall the CV for 
NAA/Cr and Cho/Cr was 3.5% and 4.1% for white matter and 4.8% and 5.2% for grey 
matter. In group 1 the CV of NAA/Cr in white matter and grey matter were 4.3 % and 5.7 
%, and in group 2 2.5 % and 3.7 %.  
 
Discussion 
 
Several  small  clinical  trials  in  MS  patients  have  used  NAA/Cr  ratios  at  the  centrum 
semiovale as surrogate outcome measure.
12,13,14,15,16 Narayanan et al reported an increase in 
NAA/Cr in 10 relapsing MS patients after being treated with interferon β for 12 months.
12 
Khan et al. reported an elevation of NAA/Cr in 18 patients in a large central brain volume 
after 2 years of treatment with glatiramer acetate.
15 An increase in NAA/Cr at the centrum 
semiovale in 11 MS patients after 2 weeks of treatment with fluoxetine was observed.
16 
These  studies  suggest  beneficial  effects  of  therapy  on  axonal  functioning  or  integrity. 
However,  interpretation  of  the  results  is  hampered  by  a  lack  of  studies  assessing 
reproducibility of NAA/Cr measurements in MS patients.  
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One study in 5 healthy subjects, assessing intraday and interday reproducibility of NAA/Cr 
ratios in the centrum semiovale found CV’s ranging between 5.1% and 7.2%.
17 Another 
study found a mean CV of 3.7 % in 6 healthy subjects scanned twice, within 15 days apart, 
at a large volume of supratentorial brain.
18 Our study for the first time shows good short-
term  (4-week  apart)  reproducibility  of  NAA/Cr  ratio  measurements  in  the  centrum 
semiovale of patients with MS.   
 
In agreement with previous studies, NAA/Cr ratios in grey matter were lower than in white 
matter.
19,20  Patients  scanned  cranially  of  the  ventricles  had  lower  NAA/Cr  and  Cho/Cr 
ratios compared to patients scanned with the ventricles partially included. Since the corpus 
callosum has the highest white matter NAA/Cr and Cho/Cr ratios, the larger area of the 
corpus callosum included in the VOI when scanning more caudally might explain this 
difference.
21 This underlines the importance of correct positioning of the VOI and voxel 
selection in longitudinal MRS studies. 
 
Our  study  indicates  that  NAA/Cr  ratio  measurements  with 
1H-MRS  at  the  centrum 
semiovale  can  be  used  as  a  reliable  surrogate  marker  of  cerebral  tissue  integrity  in 
longitudinal MS studies. Selecting the VOI above the ventricles is preferred above placing 
the VOI partially in the ventricles.   
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Abstract 
 
Axonal  degeneration  in  multiple  sclerosis  (MS)  may  be  caused  by  mitochondrial 
dysfunction  and  is  associated  with  decreased  levels  of  N-acetylaspartate  (NAA)  as 
measured  with  ¹H-magnetic  resonance  spectroscopy  (MRS).  Fluoxetine  stimulates 
astrocytic glycogenolysis, which serves as an energy source for axons. Eleven patients with 
MS received fluoxetine orally 20 mg a day during the first week, and 40 mg a day during 
the second week. The mean NAA/Creatine ratio in cerebral white matter of the MS patients 
increased from 1.77 at baseline to 1.84 at the end of the second week (p = 0.007). These 
findings  show  evidence  for  a  reversible  axonal  dysfunction  in  patients  with  MS  and 
provide a rationale for investigating whether fluoxetine has neuroprotective effects in MS. 
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Introduction 
 
Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by 
inflammation,  demyelination  and  axonal  degeneration.  Current  immunomodulatory 
therapies  reduce  inflammation  but  are  unsuccessful  in  stopping  the  progressive  axonal 
loss.
1 The pathogenesis of axonal degeneration is unclear but likely involves mitochondrial 
dysfunction  and  decreased  energy  supply.
2  Reduced  ATP  formation  impairs  the  ATP-
dependent ion-pumps, which results in accumulation of Ca
2+ in axons. This Ca
2+ overload 
will inappropriately stimulate a variety of Ca
2+ -dependent enzyme systems (e.g., calpains, 
phospholipases), leading to axonal injury.
2,3 There is evidence from in vitro studies that 
glycogen in astrocytes represents a major energy source for axons.
4 The loss of beta-2 
adrenergic receptors on astrocytes in MS may impair astrocytic glycogenolysis, and thus be 
responsible for reduced energy supply to the axons.
3 It has been shown that the selective 
serotonin re-uptake inhibitor fluoxetine stimulates glycogenolysis in cultured astrocytes.
5 
In this study we used ¹H-Magnetic Resonance Spectroscopy (¹H-MRS) of the brain to 
assess the effects of fluoxetine administration in MS patients on the levels of N-acetyl-
aspartate  (NAA),  which  is  produced  in  axonal  mitochondria  and  reflects  energy 
production.
6,7  
 
Methods 
 
All  patients  co-operated  in  the  study  with  informed  consent  and  local  medical  ethical 
committee approval. Five man and six women (age range 31-58 years) with definite MS 
participated. Seven patients had relapsing remitting MS and four secondary progressive 
MS. None of them used immunomodulatory drugs. One patient had an exacerbation three 
weeks prior to start of the study, but the others were exacerbation-free for the last six 
months. Their Expanded Disability Status Scale (EDSS) ranged from 0 to 6 (median 2.5).  
Patients received fluoxetine 20 mg once a day for seven days, followed by seven days of 
fluoxetine 20 mg twice a day. MRI scans of the brain were obtained at baseline, week 1 
and week 2 on a 1.5 T unit  (Magnetom Sonata; Siemens Medical Solutions, Erlangen, 
Germany). 
1H-MRS was preceded by the acquisition of a transverse multiple slice MRI 
series in order to position the volume of interest (VOI) containing 8 by 8 voxels of 2 cm³ 
each  above  the  lateral  ventricles.  Individual  anatomic  landmarks  were  used  for  voxel 
repositioning. Automated hybrid chemical shift imaging with point resolved spectroscopy 
(PRESS;  echo  time  135  ms,  repetition  time  1500  ms)  was  used  with  chemical  shift 
selective  excitation  (CHESS)  water  suppression.
8  Metabolite  peak  areas  were  analyzed 
bilaterally in the 12 voxels corresponding to the centrum semiovale and determined with 
Numaris software and expressed as ratios to the main creatine (Cr) signal (the 3.0 ppm 
peak).    118 
We also assessed the Timed 25-foot Walk Test (TWT, the time it takes for the patient to 
walk 25 feet), and the Abbreviated Fatigue Questionnaire (AFQ), which consists of four 
questions that have to be answered on a 7-point Likert scale.
9 A higher score indicates a 
higher degree of subjective fatigue (range 4-28). 
In  the  Statistical  Package  for  the  Social  Sciences  (SPSS  12.0  for  Windows,  Chicago, 
Illinois) the general linear model of repeated measures was used to evaluate the effects of 
fluoxetine  on  NAA/Cr  ratio  and  Choline/Creatine  (Cho/Cr)  ratio.  When  the  Wilks’ 
Lambda was significant means were compared with paired samples t-tests. Paired t-tests 
were used to assess  the effect of fluoxetine on TWT and AFQ. P-values < 0.05 were 
considered to be significant. 
 
Results 
 
The results of the effects on NAA/Cr and Cho/Cr are summarized in table 1.  
 
Table 1 The effects of fluoxetine administration in MS patients on NAA/Cr and Cho/Cr. 
  Baseline  Week 1   Week 2  P-value 
NAA/Cr ratio  
mean ± SD 
1.77  
± 0.183 
1.79 
± 0.178 
1.84 
± 0.203  
0.031 
Cho/Cr ratio 
mean ± SD 
1.06 
± 0.133 
1.07  
± 0.154 
1.06 
± 0.134 
0.841 
NAA/Cr = N-acetyl-aspartate/Creatine, Cho/Cr = Choline/Creatine 
 
The Cho/Cr ratio did not change (p=0.841). The mean NAA/Cr ratio in the cerebral white 
matter increased from 1.77 at baseline to 1.79 at week 1, and to 1.84 at week 2 (p=0.031). 
Comparison  of  means  showed  that  the  difference  between  week  0  and  week  2  was 
significant (p=0.007, 95% CI of change: 0.02-0.11). All patients’ scores of NAA/Cr, AFQ 
and TWT at baseline and week 2 are shown in table 2. Both AFQ and TWT improved after 
two weeks of fluoxetine administration, but this was not significant. 
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Table 2 The effect of 2 weeks fluoxetine administration on NAA/Cr, AFQ and TWT in 
eleven MS patients. 
Patient 
Number 
NAA/Cr 
Week 0 
NAA/Cr 
Week 2 
AFQ 
Week 0 
AFQ 
Week 2 
TWT (sec) 
Week 0 
TWT (sec) 
Week 2 
1  1.57  1.71  10  11  5.27  4.96 
2  1.99  2.06  28  24  5.31  5.78 
3  1.63  1.72  4  4  5.67  4.91 
4  1.76  1.76  19  18  11.05  11.73 
5  1.76  1.76  14  15  5.95  6.08 
6  2.06  2.07  19  21  5.04  4.73 
7  1.53  1.54  19  21  6.26  6.11 
8  1.73  1.76  12  6  7.47  7.14 
9  1.62  1.67  28  22  7.69  7.04 
10  1.85  1.93  20  14  7.15  7.02 
11  2.01  2.21  14  11  4.84  3.80 
Mean  1.77  1.84*  17.00  15.18
#  6.52  6.26
$ 
Comparison week 0 with week 2: * p=0.007; 
# p= 0.096; 
$ p=0.145 
NAA/Cr = N-acetyl-aspartate/Creatine, AFQ = Abbreviated Fatigue Questionnaire, TWT = Timed 25-feet Walk 
Test, sec = seconds. 
 
Discussion 
 
In this study we showed that short-term fluoxetine administration significantly elevated the 
NAA/Cr ratio in cerebral white matter of patients with relapsing remitting and secondary 
progressive MS. This reflects increases in NAA levels, as Cr is assumed to be relatively 
stable,
10 which was confirmed by the stable Cho/Cr ratio in our patients. The method of 
measuring NAA/Cr displays good intra-individual reproducibility.
11 After one week of 20 
mg fluoxetine administration NAA/Cr increased slightly, but with fluoxetine 40 mg given 
during the second week the elevation was significant, indicating a dose or time dependent 
response. Also fatigue, which was assessed as symptom of altered axonal metabolism, and 
walking  improved  but  these  changes  did  not  reach  significance.  In  MS,  NAA 
concentrations  in  lesions  as  well  as  normal  appearing  white  matter  are  lower  than  in 
controls,
12 indicating axonal loss or axonal metabolic dysfunction. NAA has been shown to 
be almost exclusively within neuronal cell bodies and axons, where it is synthesized by 
mitochondria. Its levels reflect the energetic state of neurons as shown, for example, by the 
concurrent decrease and recovery of NAA and ATP in an animal model of traumatic brain 
injury,
7 Further evidence relating NAA formation to mitochondrial energy production was 
obtained in studies with inhibitors of different complexes of the mitochondrial respiratory 
chain.
6 The underlying mechanism by which fluoxetine improves axonal mitochondrial   120 
energy production needs to be further explored, but may be due to its stimulatory effect on 
astrocytic glycogenolysis.
5 
Fluoxetine stimulates glycogenolysis in astrocytes by directly activating 5-HT2 receptors, 
which induces hydrolysis of glycogen probably via the phosphoinositol second messenger 
system,
5  and  by  blocking  serotonin  re-uptake,  leading  to  elevated  extracellular 
concentrations of serotonin, which also stimulates glycogenolysis.
13 Besides the effect on 
glycogenolysis, fluoxetine induces the production of astrocytic brain-derived neurotrophic 
factor (BDNF), which may also improve axonal functions in MS patients.
14,15  
Limitations of our study are the lack of a control group, the heterogeneous patient group 
and  the  use  of  single  slice  MRS,  which  covers  the  brain  only  partially.  A  placebo-
controlled  long-term  follow-up  study  evaluating  the  effects  of  fluoxetine  on  axonal 
degeneration is recommended. Brain atrophy, which is a prominent feature in MS patients, 
could  be  used  as  surrogate  marker.  This  proof-of-concept  study  shows  that  fluoxetine 
might  be  able  to  improve  the  metabolic  function  of  axons  in  MS.  Further  research  is 
necessary to evaluate whether fluoxetine has neuroprotective properties in MS.  
 
 
 
Chapter 9 Chapter 9 
  121 
References 
 
  1.   Compston A, Coles A. Multiple sclerosis. Lancet. 2002; 359; 1221-1231. 
  2.   Stys PK. General mechanisms of axonal damage and its prevention. J.Neurol.Sci. 
2005; 233; 3-13. 
  3.   De  Keyser  J,  Zeinstra  E,  Mostert  J  et  al.  Beta  2-adrenoceptor  involvement  in 
inflammatory demyelination and axonal degeneration in multiple sclerosis. Trends 
Pharmacol.Sci. 2004; 25; 67-71. 
  4.   Brown AM, Tekkok SB, Ransom BR. Glycogen regulation and functional role in 
mouse white matter. J.Physiol. 2003; 549; 501-512. 
  5.   Kong EK, Peng L, Chen Y et al. Up-regulation of 5-HT2B receptor density and 
receptor-mediated  glycogenolysis  in  mouse  astrocytes  by  long-term  fluoxetine 
administration. Neurochem.Res. 2002; 27; 113-120. 
  6.   Bates TE, Strangward M, Keelan J et al. Inhibition of N-acetylaspartate production: 
implications for 1H MRS studies in vivo. Neuroreport. 1996; 7; 1397-1400. 
  7.   Signoretti  S,  Marmarou  A,  Tavazzi  B  et  al.  N-Acetylaspartate  reduction  as  a 
measure  of  injury  severity  and  mitochondrial  dysfunction  following  diffuse 
traumatic brain injury. J.Neurotrauma. 2001; 18; 977-991. 
  8.   Sijens PE, van den Bent MJ, Nowak PJ et al. 1H chemical shift imaging reveals loss 
of brain tumor choline signal after administration of Gd-contrast. Magn Reson.Med. 
1997; 37; 222-225. 
  9.   Alberts M, Smets EM, Vercoulen JH et al. ['Abbreviated fatigue questionnaire': a 
practical tool in the classification of fatigue]. Ned.Tijdschr.Geneeskd. 1997; 141; 
1526-1530. 
  10.   De Stefano N, Narayanan S, Mortilla M et al. Imaging axonal damage in multiple 
sclerosis by means of MR spectroscopy. Neurol.Sci. 2000; 21; S883-S887. 
  11.   Rotondo E, Bruschetta G, Sacca A et al. Straightforward relative quantitation and 
age-related human standards of N-acetylaspartate at the centrum semiovale level by 
CSI (1)H-MRS. Magn Reson.Imaging. 2003; 21; 1055-1060. 
  12.   Filippi M, Rocca MA, Comi G. The use of quantitative magnetic-resonance-based 
techniques to monitor the evolution of multiple sclerosis. Lancet Neurol. 2003; 2; 
337-346. 
  13.   Cambray-Deakin  M,  Pearce  B,  Morrow  C  et  al.  Effects  of  neurotransmitters  on 
astrocyte glycogen stores in vitro. J.Neurochem. 1988; 51; 1852-1857. 
  14.   Mercier G, Lennon AM, Renouf B et al. MAP kinase activation by fluoxetine and 
its relation to gene expression in cultured rat astrocytes. J.Mol.Neurosci. 2004; 24; 
207-216.   122 
  15.   Stadelmann  C,  Kerschensteiner  M,  Misgeld  T  et  al.  BDNF  and  gp145trkB  in 
multiple sclerosis brain lesions: neuroprotective interactions between immune and 
neuronal cells? Brain. 2002; 125; 75-85. 
 
 
 
 
 
Chapter 9  
  123 
Chapter 10 
 
 
 
 
Summary & Future perspectives 
 Chapter 10 
  124 
Multiple sclerosis is a chronic disorder of the central nervous system, characterized by 
inflammation  and  axonal  degeneration.  All  current  therapies  modulate  the  peripheral 
immune system. Treatments for patients in the progressive phase of the disease, which is 
characterized by axonal degeneration, are lacking. Many MS researchers believe that early 
and strong suppression of inflammation prevents axonal degeneration. However, so far 
strong immunosuppressive treatments failed to stop disease progression. 
In 2004 a hypothesis was presented in which the lack of the beta-2 adrenergic receptor on 
astrocytes of patients with MS might explain both the inflammatory responses and the 
progressive  axonal  degeneration.  The  loss  of  beta-2  adrenergic  receptors  on  astrocytes 
reduces  the  formation  of  intracellular  cAMP  which  1)  enables  astrocytes  to  express 
interferon  gamma  induced  MHC-2  and  co-stimulatory  B7  molecules,  which  turns 
astrocytes into antigen presenting cells, and 2) decreases astrocyte lactate production that is 
transported to axons as energy source. 
If the hypothesis holds true, drugs that are able to elevate intracellular cAMP might be 
beneficial for patients with MS. These drugs might reduce both inflammation as axonal 
degeneration in MS. Since fluoxetine is able to increase cAMP signalling in astrocytes this 
drug was chosen to study in patients with MS.  
 
The  aim  of  this  thesis  was  to  study  effects  of  fluoxetine  in  patients  with  MS.  Since 
symptomatic disease activity in MS is infrequent and unpredictable, effects of medication 
are difficult to measure on clinical grounds alone. With MRI different pathophysiological 
features  of  MS  can  be  visualized  noninvasively,  and  disease  activity  can  be  easily 
monitored. We evaluated the use of MRI to monitor treatment and used a number of MRI 
techniques to study effects of fluoxetine in patients with MS.  
 
In the first part of this thesis we reviewed the effect of fluoxetine on neurological disorders 
(Chapter  2).  Fluoxetine  elevates  neurotrophic  factors,  increases  glycogenolysis  in 
astrocytes, and blocks voltage gated calcium and sodium channels, which all might prevent 
axonal  loss.  Although  we  found  many  studies  evaluating  the  use  of  fluoxetine  for 
depression in neurological disorders, no well-designed studies were available that looked at 
effects of fluoxetine on neurological function.  
 
In the second part of this thesis we performed several studies using conventional MRI. In 
chapter 3 we showed in a double-blind, placebo-controlled study that MS patients using 
fluoxetine have a tendency to have less enhancing lesions on MRI, which is a surrogate 
marker for inflammation. Effects became more apparent after 8 weeks of treatment, which 
is in line with the time it takes for fluoxetine to reach stable plasma levels and to have 
antidepressant effects. Patients using fluoxetine also had less frequent MRI scans with 
enhancing lesions. These results must be confirmed in larger studies before fluoxetine can 
get an application in clinical practice. In chapter 4 different techniques to measure brain Chapter 10 
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atrophy were compared. Except for corpus callosum area all atrophy measurements were 
moderately  to  strongly  correlated.  Brain  parenchymal  fraction  might  be  best  to  use  in 
future MS studies. Next, we wondered what the long term relevance is of measuring T2 
lesions  and  atrophy  in  patients  with  MS.  To  answer  this  question  we  re-evaluated  all 
available cerebral MRI scans of MS patients that were performed before 1997 at our clinic. 
The clinical follow-up data of all patients are registered in the Groningen MS-database. In 
chapter 5 we showed that more T2 lesions are an independent predictor for the onset of 
secondary progression. This is supported by our findings in chapter 6, which showed that 
T2 lesions are predictive for earlier progression of disability in relapsing remitting MS. 
However, in primary and secondary progressive MS the number of T2 lesions doesn’t have 
an influence on the progression of disability.  
 
In the third part of our thesis we performed several studies with ¹H-MRS. We studied 
cerebral lactate formation in healthy persons after performing a motor task (chapter 7). 
Lactate is produced by astrocytes and transported to axons as fuel during intense neural 
activity. According to our hypothesis, the astrocytic beta-2 adrenergic receptor defect in 
MS would impair the production of lactate in astrocytes. However, we could not detect 
cerebral  lactate  in  healthy  persons  and  we  concluded  that  this  activation  study  is  not 
appropriate to investigate the lactate metabolism in MS patients. In chapter 8 we looked at 
the  reproducibility  of  N-acetylaspartate/Creatine  (NAA/Cr)  after  4  weeks  in  clinically 
stable MS patients. NAA/Cr is regarded as a marker of axonal function and may be a 
suitable  marker  for  axonal  degeneration.  Good  surrogate  markers  are  valid  and 
reproducible. We showed that NAA/Cr is well reproducible after 4 weeks. The use of 
NAA/Cr in MS trials can thus be recommended. In chapter 9, we described an increase in 
NAA/Cr after two weeks of treatment with fluoxetine in an open study of 11 patients with 
relapsing  remitting  and  secondary  progressive  MS.  This  supports  possible  beneficial 
effects of fluoxetine on axonal function.  
 
Future directions 
  
Fluoxetine is cheap, world-wide available, taken orally, and safe to use long-term. This 
thesis provides a theoretical basis for the use of fluoxetine as disease modifying therapy in 
patients with MS. It contains two studies showing positive effects of fluoxetine on cerebral 
MRI measurements in patients with MS. Since these studies were small, had a maximum 
follow-up  time  of  six  months  and  did  not  use  clinical  endpoints,  the  prescription  of 
fluoxetine  as  disease  modifying  therapy  can  yet  not  be  advised.  However,  this  thesis 
justifies and encourages further studies with fluoxetine in patients with MS.  
In  patients  with  relapses  a  new  phase  2  study  could  show  whether  the  trend  towards 
improvement  we  observed  is  reproducible.  It  should  have  the  cumulative  number  of 
enhancing lesions as primary outcome measure and focus on effects of fluoxetine after 8   126 
weeks  of  treatment.  The  launch  of  a  large,  multi-center  trial,  evaluating  the  effect  of 
fluoxetine on clinical exacerbations in MS, can also be considered. Since many patients 
with  exacerbations  are  treated  with  interferon-beta  or  glatiramer  acetate  and  it  is 
unethically to withhold patients of treatment for several years, a study using fluoxetine as 
add-on treatment to current immunomodulating therapy would be the way to go. 
The effect of fluoxetine on clinical progression in primary and secondary progressive MS 
is currently investigated in a small randomized, placebo-controlled study at the University 
Medical  Center  Groningen.  Taking  into  account  the  lack  of  effective  treatment  in  the 
progressive phase of the disease, the start of a larger trial in patients with progressive forms 
of MS is an interesting option. 
The effects of fluoxetine on disease activity support the hypothesis that enhancing cAMP 
in  astrocytes  might  be  beneficial  for  patients  with  MS.  Studies  with  drugs,  other  than 
fluoxetine, that are able to enhance cAMP in astrocytes, can also be encouraged in patients 
with MS. 
 
The  cumulative  number  of  new  enhancing  lesions  and  number  of  new  T2  lesions  on 
cerebral  MRI  scans  is  frequently  used  as  surrogate  marker  for  inflammatory  disease 
activity  in  MS  studies.  However,  the  clinical  relevance  of  suppressing  these  lesions  is 
unclear.  The  finding  that  more  T2  lesions  on  cerebral  MRI  scans  increase  the  risk  of 
becoming  secondary  progressive  in  patients  with  relapsing  remitting  MS,  indicates  a 
relationship between the number of T2 lesions and secondary progression. Further studies 
must show whether suppression of new T2 lesions by immunomodulating therapies delays 
the onset of secondary progression. In patients with progressive forms of MS the number 
of T2 lesions does not predict the time to progression of disability, suggesting that T2 
lesions  have  no  influence  on  progression  of  disability  in  progressive  forms  of  MS. 
Monitoring new T2 lesions in follow-up studies can show whether increases in T2 lesions 
are  associated  with  progression  of  disability.  Currently  measurement  of  T2  lesions  in 
clinical trials of progressive forms of MS seems not useful. 
Brain atrophy is a surrogate marker for axonal degeneration and is increasingly used in MS 
trials. Although the different MRI derived atrophy measurements are strongly correlated, 
BPF might be best to use in new studies. 
New MRI techniques show abnormalities in grey and white matter that looks normal on 
conventional MRI. These techniques might provide better surrogate markers for disease 
activity  than  conventional  MRI  measurements.  Of  these,  the  use  of  MR  Spectroscopic 
derived NAA/Cr can be recommended as marker for axonal function. With diffusion tensor 
imaging and magnetization transfer imaging it is possible to quantify cerebral white and 
grey matter structures. The importance of grey matter pathology is increasingly recognized 
and is visualized with three-dimensional (3D) double inversion recovery and T1-weighted 
3D spoiled gradient-recalled echo sequences. Although technically challenging, the use of 
these techniques can also be considered. 
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We were unable to measure lactate formation with proton MR Spectroscopy. Phosphorus 
MR Spectroscopy is another technique that provides information on energy compounds 
like phosphocreatine (PCr) and adenosine triphosphate (ATP) in the CNS, and might be a 
suitable method to measure cerebral energy metabolism in MS. 
All techniques discussed should be further investigated for their suitability as surrogate 
marker for current and past disease activity in MS. Reproducibility and validity studies are 
warranted. All can be considered in new trials evaluating the use of fluoxetine in multiple 
sclerosis.  
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Multiple Sclerose (MS) is een chronisch aandoening van het centraal zenuwstelsel, welke 
gekenmerkt wordt door inflammatoire demyelinisatie en axonale degeneratie. Alle huidige 
medicijnen  werken  op  het  perifere  immuunsysteem.  Voor  de  progressieve  fase  van  de 
ziekte, waarin axonale degeneratie op de voorgrond staat, zijn er geen bewezen effectieve 
medicijnen. Veel MS onderzoekers geloven dat vroege en agressieve onderdrukking van de 
ontstekingen  axonale  degeneratie  voorkomt.  Tot  nu  toe  heeft  agressieve 
immunosuppressieve therapie echter de ziekte nog niet tot stilstand gebracht. 
In 2004 hebben we een hypothese gepresenteerd die gebaseerd is op het ontbreken van de 
beta-2 adrenerge receptoren op astrocyten bij patienten met MS. Het verlies van de beta-2 
adrenerge  receptoren  zorgt  voor  een  verminderde  cAMP  productie  in  de  astrocyt  wat 
ervoor zorgt dat:  
1)  astrocyten  door  interferon-gamma  geinduceerd  MHC  klasse  2  tot  expressie  kunnen 
brengen, waardoor de astrocyt een antigeen presenterende cel wordt, en dus een cruciale 
rol gaat spelen in het ontstekingsproces  
2) in de astrocyt de productie van lactaat, wat naar het axon wordt getransporteerd wordt 
als energiebron, is afgenomen. Hierdoor ontstaat een energietekort in het axon waardoor 
deze degenereert. 
Als de hypothese klopt, dan kunnen medicijnen die cAMP doen stijgen in astrocyten zowel 
de  ontsteking  als  de  axonale  degeneratie  in  MS  doen  afnemen.  Aangezien  het 
antidepressivum fluoxetine hiertoe in staat is, is besloten om de effecten van dit medicijn te 
onderzoeken bij patienten met MS.  
De  ziekte  activiteit  in  MS  is  onregelmatig,  onvoorspelbaar  en  moeilijk  op  klinische 
gronden vast te leggen en te meten. Met behulp van MRI is het mogelijk om verschillende 
pathofysiologische  kenmerken  van  de  ziekte  noninvasief  te  bekijken  en  te  vervolgen. 
Ziekteactiviteit op de MRI kan gevonden worden zonder dat patienten klachten hebben. 
 
In  het  eerste  deel  van  dit  proefschrift  bekijken  we  de  effecten  van  fluoxetine  op 
neurologische aandoeningen (hoofdstuk 2). Fluoxetine verhoogt neurotrofe factoren, geeft 
een toename van de glycogenolyse in astrocyten, en blokkeert calcium en natrium kanalen. 
Dit kan axonale schade voorkomen. Alhoewel er veel studies zijn waarin het gebruik van 
fluoxetine  voor  de  behandeling  van  depressie  bij  neurologische  aandoeningen  is 
onderzocht,  ontbreken  er  goed  opgezette  studies  naar  de  effecten  van  fluoxetine  op 
neurologische klachten. 
 
In  het  volgende  deel  van  dit  proefschrift  voeren  we  enkele  studies  met  behulp  van 
conventionele MRI uit.  
In hoofdstuk 3 laten we in een dubbel-blind, placebo-gecontroleerd onderzoek zien dat het 
gebruik van fluoxetine door niet depressieve MS patienten leidt tot een trend tot afname 
van het aantal aankleurende lesies op de MRI van het cerebrum. Het aantal aankleurende 
lesies  is  een  surrogaatmarker  voor  de  ontstekingsactiviteit  bij  patienten  met  MS.  Deze Chapter 11 
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trend werd duidelijker na 8 weken behandeling, wat overeenkomt met de tijd dat het duurt 
om stabiele plasmalevels van fluoxetine te bereiken en om antidepressieve werking van 
fluoxetine te kunnen zien. Patienten die fluoxetine gebruikten, hadden ook minder MRI 
scans  waarop  ontstekingsactiviteit  werd  gevonden.  Grotere  studies  zijn  nodig  voordat 
fluoxetine een plaats kan krijgen in de behandeling van MS. Hoofdstuk 4 beschrijft de 
vergelijking van verschillende technieken om hersenatrofie te meten. Op corpus callosum 
area na, waren alle atrofiemetingen redelijk goed tot sterk aan elkaar gecorreleerd. Brain 
parenchymal fraction leek de meest geschikte methode om te gebruiken in toekomstige MS 
studies.  
Vervolgens vroegen wij ons af wat de klinische relevantie is van het meten van T2 lesies 
en hersenatrofie bij mensen met MS. Om hier meer inzicht in te verkrijgen, hebben we alle 
cerebrale  MRI  scans  van  MS  patienten,  die  verricht  waren  voor  1997,  proberen  te 
verkrijgen. Deze hebben we geanalyseerd met betrekking tot het aantal T2 lesies en een 
aantal  hersenatrofiematen.  Alle  klinische  patientengegevens  werden  bijgehouden  in  de 
Groningen MS-database. In hoofdstuk 5 laten we zien dat meer T2 lesies op de oude MRI 
scan een onafhankelijke voorspeller is voor het eerder optreden van secundaire progressie. 
Dit wordt ondersteund door onze bevindingen dat meer T2 lesies een voorspellende factor 
zijn voor het eerder optreden van toename van beperkingen (hoofdstuk 6). In de primaire 
en secundair progressieve beloopsvormen van MS hebben het aantal T2 lesies geen invloed 
op het ontstaan van nieuwe beperkingen. 
 
In het laatste deel van dit proefschrift hebben we verschillende studies uitgevoerd met ¹H-
MRS.  We  hebben  geprobeerd  om  lactaat  te  meten  bij  gezonde  proefpersonen  die  
knijpbewegingen uitvoerden (hoofdstuk 7). Lactaat wordt geproduceerd door astrocyten en 
wordt  getransporteerd  naar  axonen  als  brandstof  tijdens  intensieve  neuronale  activiteit. 
Volgens  onze  hypothese  is  de  productie  van  lactaat  in  astrocyten  verstoord  door  het 
ontbreken van de beta-2 adrenerge receptoren. Als we lactaat hadden kunnen detecteren, 
wilden we hetzelfde onderzoek doen bij mensen met MS. We konden echter geen lactaat 
vinden bij gezonde personen en moeten concluderen dat onze methode niet geschikt is om 
het lactaat metabolisme te meten.  
In  hoofdstuk  8  hebben  we  gekeken  naar  de  reproduceerbaarheid  van  N-
acetylaspartate/Creatine (NAA/Cr) na 4 weken bij klinisch stabiele MS patienten. NAA/Cr 
is een surrogaatmarker voor axonale functie en mogelijk ook voor axonale degeneratie. 
Goede surrogaatmarkers zijn valide en reproduceerbaar. We laten zien dat NAA/Cr  goed 
reproduceerbaar is na 4 weken en het gebruik van NAA/Cr kan dus worden aanbevolen in 
MS trials. Als laatste beschrijven we in een open studie bij 11 MS patienten een toename 
van NAA/Cr nadat ze 2 weken fluoxetine gebruikt hebben (hoofdstuk 9). Dit ondersteunt 
een mogelijk gunstig effect van fluoxetine op axonale functie. 
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Toekomstige richtingen 
 
Fluoxetine is goedkoop, wereldwijd beschikbaar, beschikbaar in tabletvorm en veilig bij 
langdurig  gebruik.  Dit  proefschrift  geeft  een  theoretische  basis  voor  het  gebruik  van 
fluoxetine als ziektemodulerend medicijn bij patienten met MS. Het bevat 2 studies met 
positieve  effecten  van  fluoxetine  op  cerebrale  MRI  metingen  bij  mensen  met  MS. 
Aangezien  deze  studies  klein  zijn  en  slechts  een  maximale  follow-up  hebben  van  6 
maanden zonder dat er gebruik gemaakt is van klinische eindpunten, is het te vroeg om 
fluoxetine  aan patienten met MS  voor te schrijven.  Wel  moedigen  de resultaten in  dit 
proefschrift nader onderzoek naar de effecten van fluoxetine bij mensen met MS aan. 
Bij patienten met relapsing-remitting MS kan een nieuwe fase 2 studie aantonen of de 
trend tot verbetering met fluoxetine reproduceerbaar is. Als primaire uitkomstmaat zou dan 
ook het cumulatieve aantal aankleurende T1 lesies gebruikt kunnen worden waarbij dan de 
nadruk moet liggen op de effecten van fluoxetine na 8 weken. Het starten van een grote, 
multi-center trial naar de effecten van fluoxetine op klinische exacerbaties bij MS kan ook 
overwogen  worden.  Aangezien  veel  patienten  met  exacerbaties  behandeld  worden  met 
interferon-beta  of  glatirameer-acetaat  en  het  onethisch  is  om  mensen  meerdere  jaren 
behandeling te ontzeggen, is een studie waarbij fluoxetine als toevoeging gegeven wordt 
aan huidige immunomodulerende therapie een goede optie. Het effect van fluoxetine op 
toename van beperkingen bij mensen met primair en secundair progressieve MS wordt 
momenteel onderzocht in een kleine gerandomiseerde, placebo-gecontroleerde studie in het 
Universitair  Medisch  Centrum  Groningen.  Een  grotere  studie  naar  de  effecten  van 
fluoxetine  op  progressieve  beloopsvormen  van  MS  valt  te  overwegen,  zeker  omdat 
effectieve behandelingen in de progressieve fase van de ziekte ontbreken. 
De effecten van fluoxetine op ziekte activiteit ondersteunen de hypothese dat een toename 
van cAMP in astrocyten voordelig kan zijn voor patienten met MS. Studies met andere 
medicijnen, die de hoeveelheid cAMP doen toenemen in astrocyten, kunnen aangemoedigd 
worden. 
 
Het cumulatieve aantal aankleurende lesies en aantal nieuwe T2 lesies op cerebrale MRI-
scans is vaak gebruikt als surrogaat marker voor ontstekingsactiviteit in MS onderzoeken. 
De klinische relevantie van het onderdrukken van deze lesies is onduidelijk. Het feit dat 
meer T2 lesies op cerebrale MRI scans een voorspellende waarde hebben voor het optreden 
van secundaire progressie, geeft aan dat er een verband kan bestaan tussen het aantal T2 
lesies en secundaire progressie. Nieuwe studies moeten laten zien of het onderdrukken van 
nieuwe  T2  lesies  met  immunomodulerende  therapie  het  begin  van  de  secundair 
progressieve fase uitstelt. Bij patienten met progressieve beloopsvormen van MS voorspelt 
het  aantal  T2  lesies  niet  de  tijd  tot  het  optreden  van  toename  van  beperkingen.  Dit 
suggereert  dat  T2  lesies  geen  invloed  hebben  op  het  optreden  van  toename  van 
beperkingen in progressieve vormen van MS. Vervolgstudies kunnen laten zien of een 
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toename  van  het  aantal  T2  lesies  geassocieerd  is  met  een  toename  van  beperkingen. 
Momenteel lijkt het meten van T2 lesies in studies met progressieve beloopsvormen van 
MS niet zinvol. 
Hersenatrofie is een surrogaat marker voor axonale degeneratie en wordt in toenemende 
mate gebuikt in MS studies. Alhoewel de verschillende manieren om atrofie te bepalen 
sterk met elkaar correleren, lijkt de Brain Parenchymal Fraction (BPF) het meest geschikt 
om te gebruiken in nieuwe studies. 
Nieuwere MRI technieken laten afwijkingen zien in de grijze en witte stof die er normaal 
uitziet op de conventionele MRI. Deze technieken zouden betere surrogaatmarkers kunnen 
zijn voor ziekte activiteit dan de metingen bepaald met conventionele MRI. Het gebruik 
van NAA/Cr, bepaald met MR spectroscopie, kan aanbevolen worden als marker voor 
axonale functie. Met diffusion tensor imaging en magnetization transfer imaging is het 
mogelijk om de cerebrale witte en grijze stof te kwantificeren. Het belang van grijze stof 
pathologie  wordt  in  toenemende  mate  ingezien  en  kan  aangetoond  worden  met  three 
dimensional (3D) double inversion recovery en T1-weighted 3D spoiled gradient-recalled 
echo  sequences.  Alhoewel  deze  technieken  technisch  ingewikkeld  zijn,  is  het  gebruik 
hiervan het overwegen waard. 
We  konden  geen  lactaat  meten  met  proton  MR  Spectroscopie.  Phosphorus  MR 
spectroscopie  is  een  andere  techniek  waarmee  stoffen  die  een  rol  spelen  in  de 
energiehuishouding, zoals phophscreatine (PCr) en adenosine triphosphate (ATP), in het 
CZS gemeten kunnen worden. Deze techniek zou dus een betere methode kunnen zijn om 
het cerebrale energie metabolisme bij MS te meten. 
Alle besproken technieken  zouden verder onderzocht moeten worden om hun geschiktheid 
te  bepalen  als  surrogaatmarker  voor  actieve  en  eerdere  ziekteactiviteit.  Studies  naar 
reproduceerbaarheid  en  validiteit  zijn  nodig.  Bij  nieuwe  studies  naar  effecten  van 
fluoxetine zouden deze technieken gebruikt kunnen worden.   
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